BLOOD CANCER UNITED INC: Form 990, tax year 2020
View the entire original 990 at ProPublica ↗
- Organization
- BLOOD CANCER UNITED INC (EIN 13-5644916)
- Tax period
- 2020-07-01 to 2021-06-30
- Filed
- 2022-02-07
- IRS object ID
- 202230389349301103
- Schema version
- 2020v4.0
- Source
- Download XML · Original 990 at ProPublica
Every field in the e-filed return. Faint text is the IRS element name, for citing.
- Return header
- Form 990
- Schedule A
- Schedule B
- Schedule C
- Schedule D
- Schedule F
- Schedule G
- Schedule I
- Schedule J
- Schedule M
- Schedule O
- Schedule R
Return header ReturnHeader
| Field | Value | IRS element (for citing) |
|---|---|---|
| Return | 2022-02-07T12:50:17-06:00 | ReturnTs |
| Tax Period End | 2021-06-30 | TaxPeriodEndDt |
Preparer Firm PreparerFirmGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Preparer Firm EIN | 135565207 | PreparerFirmEIN |
Preparer Firm Name PreparerFirmName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | KPMG LLP | BusinessNameLine1Txt |
Preparer US Address PreparerUSAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 345 PARK AVENUE | AddressLine1Txt |
| City | NEW YORK | CityNm |
| State Abbreviation | NY | StateAbbreviationCd |
| ZIP | 101540102 | ZIPCd |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Return Type | 990 | ReturnTypeCd |
| Tax Period Begin | 2020-07-01 | TaxPeriodBeginDt |
Filer Filer
| Field | Value | IRS element (for citing) |
|---|---|---|
| EIN | 135644916 | EIN |
Business Name BusinessName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | THE LEUKEMIA & LYMPHOMA SOCIETYINC | BusinessNameLine1Txt |
| Business Name Line2 | INC | BusinessNameLine2Txt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Control | LEUK | BusinessNameControlTxt |
| Phone | 9149495213 | PhoneNum |
US Address USAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 7111 WEST 151 STREET PMB 317 | AddressLine1Txt |
| City | OVERLAND PARK | CityNm |
| State Abbreviation | KS | StateAbbreviationCd |
| ZIP | 66223 | ZIPCd |
Business Officer BusinessOfficerGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Person | GORDON MILLER JR | PersonNm |
| Person Title | EVP CHIEF FIN OFFICE | PersonTitleTxt |
| Phone | 3125687727 | PhoneNum |
| Signature | 2022-02-02 | SignatureDt |
| Discuss With Paid Preparer | Yes (true) | DiscussWithPaidPreparerInd |
Signing Officer SigningOfficerGrp
Person Full Name PersonFullName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Person First | GORDON | PersonFirstNm |
| Person Last | MILLER | PersonLastNm |
| Field | Value | IRS element (for citing) |
|---|---|---|
| SSN | XXX-XX-XXXX | SSN |
Preparer Person PreparerPersonGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Preparer Person | DAVID M HIGHFILL | PreparerPersonNm |
| PTIN | P01517891 | PTIN |
| Phone | 2127589700 | PhoneNum |
| Preparation | 2022-02-02 | PreparationDt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Tax | 2020 | TaxYr |
| Build TS | 2022-09-23 18:48:47Z | BuildTS |
Form 990 IRS990
| Field | Value | IRS element (for citing) |
|---|---|---|
| Principal Officer | LOUIS J DEGENNARO | PrincipalOfficerNm |
US Address USAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 3 INTERNATIONAL DRIVE SUITE 200 | AddressLine1Txt |
| City | RYE BROOK | CityNm |
| State Abbreviation | NY | StateAbbreviationCd |
| ZIP | 10573 | ZIPCd |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Gross Receipts | $538,944,536 | GrossReceiptsAmt |
| Group Return For Affiliates | false | GroupReturnForAffiliatesInd |
| Organization501c3 | Yes (X) | Organization501c3Ind |
| Website Address | WWW.LLS.ORG | WebsiteAddressTxt |
| Type Of Organization Corp | Yes (X) | TypeOfOrganizationCorpInd |
| Formation | 1949 | FormationYr |
| Legal Domicile State | NY | LegalDomicileStateCd |
| Activity Or Mission | OUR MISSION IS TO CURE LEUKEMIA, LYMPHOMA, HODGKIN'S DISEASE AND MYELOMA, AND IMPROVE THE QUALITY OF LIFE OF PATIENTS AND THEIR FAMILIES. | ActivityOrMissionDesc |
| Voting Members Governing Body | 19 | VotingMembersGoverningBodyCnt |
| Voting Members Independent | 19 | VotingMembersIndependentCnt |
| Total Employee | 1300 | TotalEmployeeCnt |
| Total Volunteers | 3000000 | TotalVolunteersCnt |
| Total Gross UBI | $0 | TotalGrossUBIAmt |
| PY Contributions Grants | $427,419,530 | PYContributionsGrantsAmt |
| CY Contributions Grants | $441,317,494 | CYContributionsGrantsAmt |
| PY Program Service Revenue | $15,997,252 | PYProgramServiceRevenueAmt |
| CY Program Service Revenue | $12,281,240 | CYProgramServiceRevenueAmt |
| PY Investment Income | $33,847,009 | PYInvestmentIncomeAmt |
| CY Investment Income | $12,298,324 | CYInvestmentIncomeAmt |
| PY Other Revenue | $18,957,518 | PYOtherRevenueAmt |
| CY Other Revenue | $11,766,658 | CYOtherRevenueAmt |
| PY Total Revenue | $496,221,309 | PYTotalRevenueAmt |
| CY Total Revenue | $477,663,716 | CYTotalRevenueAmt |
| PY Grants And Similar Paid | $169,606,729 | PYGrantsAndSimilarPaidAmt |
| CY Grants And Similar Paid | $152,554,274 | CYGrantsAndSimilarPaidAmt |
| CY Benefits Paid To Members | $0 | CYBenefitsPaidToMembersAmt |
| PY Salaries Comp Emp Bnft Paid | $126,383,366 | PYSalariesCompEmpBnftPaidAmt |
| CY Salaries Comp Emp Bnft Paid | $113,748,897 | CYSalariesCompEmpBnftPaidAmt |
| PY Total Prof Fndrsng Expns | $4,373,282 | PYTotalProfFndrsngExpnsAmt |
| CY Total Prof Fndrsng Expns | $9,126,288 | CYTotalProfFndrsngExpnsAmt |
| CY Total Fundraising Expense | $54,854,964 | CYTotalFundraisingExpenseAmt |
| PY Other Expenses | $93,633,073 | PYOtherExpensesAmt |
| CY Other Expenses | $84,418,720 | CYOtherExpensesAmt |
| PY Total Expenses | $393,996,450 | PYTotalExpensesAmt |
| CY Total Expenses | $359,848,179 | CYTotalExpensesAmt |
| PY Revenues Less Expenses | $102,224,859 | PYRevenuesLessExpensesAmt |
| CY Revenues Less Expenses | $117,815,537 | CYRevenuesLessExpensesAmt |
| Total Assets BOY | $581,677,610 | TotalAssetsBOYAmt |
| Total Assets EOY | $743,613,782 | TotalAssetsEOYAmt |
| Total Liabilities BOY | $215,555,172 | TotalLiabilitiesBOYAmt |
| Total Liabilities EOY | $229,841,284 | TotalLiabilitiesEOYAmt |
| Net Assets Or Fund Balances BOY | $366,122,438 | NetAssetsOrFundBalancesBOYAmt |
| Net Assets Or Fund Balances EOY | $513,772,498 | NetAssetsOrFundBalancesEOYAmt |
| Info In Schedule O Part III | Yes (X) | InfoInScheduleOPartIIIInd |
| Mission | OUR MISSION IS TO CURE LEUKEMIA, LYMPHOMA, HODGKIN'S DISEASE AND MYELOMA, AND IMPROVE THE QUALITY OF LIFE OF PATIENTS AND THEIR FAMILIES. | MissionDesc |
| Significant New Program Srvc | false | SignificantNewProgramSrvcInd |
| Significant Change | false | SignificantChangeInd |
| Expense | $59,637,481 | ExpenseAmt |
| Grant | $33,928,340 | GrantAmt |
| Revenue | $12,281,240 | RevenueAmt |
| Desc | A) RESEARCH PROGRAMS: AT LLS, WE ARE PUSHING BOUNDARIES TOWARD POWERFUL NEW THERAPIES. WE PROPEL GROUNDBREAKING CANCER TREATMENTS THROUGH ALL PHASES OF THE DRUG APPROVAL PROCESS AND ARE PROUD THAT OUR SUPPORT HAS BEEN KEY TO ADVANCING 75% OF THE ALMOST 100 BLOOD CANCER TREATMENT APPROVALS OVER THE LAST FIVE YEARS. AS WE CONTINUED TO SUPPORT THE SEARCH FOR LIFESAVING AND LESS TOXIC TREATMENTS IN 2021, WE INVESTED IN EXCITING RESEARCH FRONTIERS, INCLUDING PRECISION MEDICINE, IMMUNOTHERAPY, AND LINKS BETWEEN MUTATIONS AND BLOOD CANCER-ADVANCEMENTS THAT ARE CHANGING THE PARADIGM OF CANCER TREATMENT. IN THE PROCESS, WE PROPELLED SEVERAL NOVEL SCIENCE INITIATIVES TO NEW HEIGHTS-MANY OF WHICH HARDLY SEEMED POSSIBLE JUST A SHORT TIME AGO. WITH ADVISORY INPUT FROM RECOGNIZED BIOMEDICAL RESEARCH EXPERTS, LLS FUNDS EXEMPLARY PROJECTS ACROSS THE ENTIRE RESEARCH CONTINUUM RELEVANT TO IMPROVE OUTCOMES FOR BLOOD CANCER PATIENTS, FROM BASIC LABORATORY SCIENCE THROUGH CLINICAL TRIALS, AND FROM INVESTIGATOR-INITIATED RESEARCH TO PRIVATE-SECTOR DRUG DEVELOPMENT ALLIANCES. LLS IS DELIBERATE AND PURPOSEFUL IN FINDING AND SUPPORTING RESEARCH THAT IS MOST LIKELY TO HELP PATIENTS AS SOON AS POSSIBLE. TO DATE, LLS HAS INVESTED OVER 1.5 BILLION IN RESEARCH AIMED AT HELPING ALL BLOOD CANCER PATIENTS LIVE BETTER, LONGER LIVES. IN FISCAL YEAR 2021, LLS SUPPORTED RESEARCH IN THE U.S., CANADA AND 6 OTHER COUNTRIES WITH A TOTAL RESEARCH DISBURSEMENT OF APPROXIMATELY 33.9 MILLION. RESEARCH FUNDING WAS DISTRIBUTED ACROSS ALL BLOOD CANCERS. IMPACT RESEARCH GRANTS TO ADDRESS UNEQUAL REPRESENTATION OF UNDERSERVED POPULATIONS IN CLINICAL TRIALS, IN MAY WE INTRODUCED IMPACT (INFLUENTIAL MEDICINE PROVIDING ACCESS TO CLINICAL TRIALS) RESEARCH GRANTS. AN INITIAL FIVE-YEAR INVESTMENT OF 3.75 MILLION WAS ALLOCATED TO MAYO CLINIC, VANDERBILT UNIVERSITY MEDICAL CENTER, AND WEILL CORNELL MEDICINE IN NEW YORK CITY. THE IMPACT GRANTS WILL HELP THESE MAJOR CANCER CENTERS EXPAND CLINICAL TRIAL ACCESS TO LOCAL COMMUNITY-BASED HOSPITALS AND CLINICS WITH SUBSTANTIAL UNDERSERVED POPULATIONS. THE GOAL IS TO INCREASE TRIAL ENROLLMENT AMONG TRADITIONALLY UNDERSERVED POPULATIONS, INCLUDING RACIAL AND ETHNIC MINORITIES, RURAL RESIDENTS, AND INDIVIDUALS WITH LOW INCOME, TO AT LEAST 20%, THEREBY EXPANDING ACCESS TO STATE-OF-THE-ART THERAPIES TO A BROADER SWATH OF NEWLY DIAGNOSED BLOOD CANCER PATIENTS. THERAPY ACCELERATION PROGRAM (TAP) SINCE 2007, OUR INNOVATIVE VENTURE PHILANTHROPY INITIATIVE, THE LLS THERAPY ACCELERATION PROGRAM (TAP), HAS PARTNERED WITH BIOTECHNOLOGY COMPANIES AND ACADEMIC RESEARCHERS TO EXTEND THE THERAPEUTIC LANDSCAPE IN LEUKEMIA, LYMPHOMA, AND MULTIPLE MYELOMA. IN 2021, WE MADE SIX NEW INVESTMENTS IN COMPANIES DEVELOPING NEW IMMUNOTHERAPIES INCLUDING "OFF THE SHELF" CAR T-CELL THERAPY, "IN VIVO" THERAPY THAT GENERATES CANCER-FIGHTING CAR CELLS INSIDE THE BODY, TWO FIRST-IN-CLASS ANTIBODIES TARGETING NOVEL CHECKPOINTS, TO RELEASE THE BRAKES AND ACTIVATE IMMUNE CELLS SO THEY CAN FIGHT CANCER, AND CAR- MACROPHAGE (CAR-M) THERAPY TO TREAT CANCERS WHERE CHECKPOINT INHIBITORS TEND TO BE LESS EFFECTIVE. NATIONAL PATIENT REGISTRY COVID INFORMATION THE ONGOING COVID-19 PANDEMIC ENGENDERED A HOST OF FEARS AND QUESTIONS FOR THE BLOOD CANCER COMMUNITY. WHEN PATIENT CONCERNS AROSE ABOUT WHETHER THE NEW VACCINES WOULD PROTECT THEM, LLS STEPPED IN TO FIND ANSWERS. IN FEBRUARY 2021, LLS ACTIVATED THE LLS NATIONAL PATIENT REGISTRY, A PROJECT SUPPORTED BY ETHEL AND BERNARD GARIL IN MEMORY OF THEIR SON, MICHAEL, WHO SUCCUMBED TO ACUTE LYMPHOBLASTIC LEUKEMIA. MORE THAN 10,000 BLOOD CANCER PATIENTS ANSWERED THE CALL TO JOIN THE REGISTRY AS "CITIZEN SCIENTISTS." THIS ALLOWED US TO GENERATE THE LARGEST DATA SET REPORTED TO DATE ON VACCINE SAFETY AND EFFICACY(INCLUDING BOOSTERS) ACROSS ALL MAJOR BLOOD CANCER AND TREATMENT TYPES. THIS INFORMATION HAS HELPED PATIENTS, HEALTHCARE PROVIDERS, AND PUBLIC HEALTH OFFICIALS MAKE MORE INFORMED CHOICES ABOUT COVID-19 PREVENTION. CLINICAL TRIALS BEAT AML MASTER TRIAL BEGINNING NOVEMBER 2016, LLS LAUNCHED THE BEAT AML MASTER TRIAL, A COLLABORATIVE CLINICAL TRIAL TESTING SEVERAL NOVEL TARGETED THERAPIES FOR PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) DESIGNED TO FACILITATE FDA APPROVAL OF NEW DRUGS AND CHANGE THE TREATMENT PARADIGM FOR PATIENTS DIAGNOSED WITH AML BY DEVELOPING MORE INDIVIDUALIZED, EFFECTIVE TREATMENT APPROACHES. THE MASTER TRIAL INVOLVES COLLABORATIONS WITH MULTIPLE MEDICAL INSTITUTIONS, DRUG COMPANIES, A GENOMIC PROVIDER, A CLINICAL RESEARCH ORGANIZATION, AND THE FDA, ALL OF WHOM HAVE COMMITTED TO WORKING COLLABORATIVELY. IN FISCAL YEAR 2021, UP TO 35 PATIENTS PARTICIPATED IN CLINICAL TRIALS UNDER THE BEAT AML MASTER TRIAL. | Desc |
Prog Srvc Accom Acty2 ProgSrvcAccomActy2Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Expense | $164,688,249 | ExpenseAmt |
| Grant | $118,625,934 | GrantAmt |
| Desc | B) PATIENT & COMMUNITY SERVICES: AN ESTIMATED 1.3 MILLION PEOPLE ACROSS THE UNITED STATES (US) ARE CURRENTLY LIVING WITH OR ARE IN REMISSION FROM LEUKEMIA, LYMPHOMA AND MYELOMA. THE LEUKEMIA & LYMPHOMA SOCIETY (LLS) OFFERS AN ARRAY OF FREE, COMPREHENSIVE RESOURCES TO BLOOD CANCER PATIENTS, CAREGIVERS, FAMILIES AND FRIENDS OF PATIENTS, ADVOCATES, HEALTHCARE PROFESSIONALS AND THE PUBLIC. LLS IS COMMITTED TO PROVIDING THE MOST ACCURATE AND UP-TO-DATE BLOOD CANCER INFORMATION. PROFESSIONAL VOLUNTEER CLINICAL ADVISORS WORK WITH LLS STAFF TO REVIEW ALL OF THE INFORMATION LLS PROVIDES THROUGH HEALTHCARE PROFESSIONAL AND PATIENT EDUCATION PROGRAMS, PUBLICATIONS AND THE LLS WEBSITE. SUPPORT SERVICES ARE PROVIDED BY PROFESSIONALS OR RIGOROUSLY TRAINED PEER VOLUNTEERS. ALL RESOURCES ARE PROVIDED THROUGH A VARIETY OF MEDIA - PRINT, ONLINE, BY PHONE, AND FACE-TO-FACE IN COMMUNITIES. A NUMBER OF RESOURCES ARE AVAILABLE IN SPANISH FOR PATIENTS, CAREGIVERS AND HEALTHCARE PROFESSIONALS. FINANCIAL ASSISTANCE OUR FINANCIAL ASSISTANCE PROGRAMS AIM TO LESSEN THE ECONOMIC TOLL ON PATIENTS AND FAMILIES TO HELP PATIENTS AFFORD LIFE-SAVING TREATMENTS. TO COUNTER CONTINUALLY RISING DRUG PRICES AND THE ONGOING FINANCIAL IMPACT OF COVID-19, WE PROVIDED MORE THAN 45,000 PATIENTS WITH OVER 241M IN TOTAL GRANTS, A 70% INCREASE OVER LAST YEAR. THE LION'S SHARE-OVER 234 MILLION- SUPPORTED PATIENTS' INSURANCE PREMIUMS AND TREATMENT-RELATED CO-PAY AND CO-INSURANCE OUT OF POCKET COSTS THROUGH OUR CO-PAY ASSISTANCE PROGRAM. IN KEEPING WITH OUR COMMITMENT TO DIVERSITY, EQUITY, AND INCLUSION, LLS RECOGNIZES THAT NEED EXISTS THROUGHOUT ALL GEOGRAPHIC REGIONS AND WITHIN ALL PATIENT POPULATIONS, INCLUDING THOSE TRADITIONALLY UNDERREPRESENTED. IN 2021, FINANCIAL ASSISTANCE WAS PROVIDED TO PATIENTS WHO RESIDED IN 55% OF ALL U.S. COUNTIES AND 51% OF THE COUNTIES ACROSS THE U.S. WITH THE HIGHEST POVERTY RATES. CO-PAY ASSISTANCE PROGRAM THE CO-PAY ASSISTANCE PROGRAM SUPPORTS QUALIFYING BLOOD CANCER PATIENTS MEET THEIR HEALTH INSURANCE OR MEDICARE PLAN PART B OR D PREMIUMS OR CO- PAYMENT OBLIGATIONS RELATED TO TREATING THEIR BLOOD CANCER DIAGNOSIS. PATIENTS WITH PRESCRIPTION DRUG COVERAGE, MEDICARE BENEFICIARIES UNDER MEDICARE PART B AND/OR MEDICARE PART D, MEDICARE SUPPLEMENTARY HEALTH INSURANCE OR MEDICARE ADVANTAGE SHOULD CHECK WITH LLS TO SEE IF THEY MEET ELIGIBILITY REQUIREMENTS TO RECEIVE FINANCIAL SUPPORT. CO-PAY ASSISTANCE IS SUBJECT TO FUNDING AVAILABILITY BY SPECIFIC BLOOD CANCER DIAGNOSIS. IN 2021, CO-PAY ASSISTANCE WAS PROVIDED TO OVER 22,000 PATIENTS. SUSAN LANG PRE CAR T-CELL THERAPY TRAVEL ASSISTANCE PROGRAM LLS PROVIDED OVER 200 GRANTS, EACH 2,500, FOR TREATMENT-RELATED TRANSPORTATION AND LODGING COSTS FOR PATIENTS WHO ARE BEING EVALUATED TO RECEIVE CAR T-CELL THERAPY AS EITHER STANDARD TREATMENT OR A CLINICAL TRIAL. SUSAN LANG PAY-IT-FORWARD PATIENT TRAVEL ASSISTANCE PROGRAM LLS AWARDED A 500 GRANT TO OVER 4,750 PATIENTS FOR TREATMENT-RELATED TRANSPORTATION AND LODGING COSTS. URGENT NEED PROGRAM IN PARTNERSHIP WITH MOPPIE'S LOVE AND CHARLIE'S FUND, LLS PROVIDED A 500 GRANT TO NEARLY 9,000 PATIENTS AND FAMILIES IN ACUTE FINANCIAL NEED FOR NON-MEDICAL LIVING EXPENSES-INCLUDING RENT, UTILITIES AND FOOD. PATIENT AID PROGRAM LLS PROVIDED A ONE-TIME STIPEND OF 100 TO OVER 3,700 PATIENTS TO HELP OFFSET NON-MEDICAL EXPENSES. SCHOLARSHIP FOR BLOOD CANCER SURVIVORS NEW IN 2021 WAS THE INTRODUCTION OF LLS'S SCHOLARSHIP FOR BLOOD CANCER SURVIVORS PROVIDING UP TO 7,500 IN TUITION SUPPORT FOR PATIENTS DIAGNOSED BEFORE AGE 25, ARE U.S. CITIZENS OR PERMANENT RESIDENTS PURSUING VIRTUAL OR IN-PERSON, VOCATIONAL, 2 YEAR OR 4 YEAR POST-SECONDARY EDUCATION. | Desc |
Prog Srvc Accom Acty3 ProgSrvcAccomActy3Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Expense | $21,415,572 | ExpenseAmt |
| Desc | C) PUBLIC HEALTH EDUCATION: LLS BELIEVES KNOWLEDGE IS POWER. AS ALWAYS, LLS HAS OFFERED THEIR INFORMATIONAL PROGRAMS IN VIRTUAL FORMATS, CONTINUING TO PROVIDE VITALLY NEEDED EDUCATION AND EMOTIONAL SUPPORT FOR THOSE IMPACTED BY BLOOD CANCER. ONGOING PANDEMIC CONCERNS TRAINED ONCOLOGY INFORMATION SPECIALISTS IN OUR INFORMATION RESOURCE CENTER (IRC) WERE AVAILABLE TO ANSWER PANDEMIC-RELATED AND OTHER QUESTIONS. OVER 26,000 INTERACTIONS BETWEEN THE IRC AND PATIENTS AND CAREGIVERS TOOK PLACE, WITH AVERAGE CALL LENGTHS UP 30% OVER 2020. FACILITATING CLINICAL TRIAL ACCESS THE LLS CLINICAL TRIAL SUPPORT CENTER (CTSC) GREW THROUGHOUT THE YEAR AS WE INCREASED OUR BI-LINGUAL AND PEDIATRIC EXPERTISE AMONG THE CTSC NURSE NAVIGATORS, AND CONTINUED TO EXPAND THE POSSIBILITY OF POSITIVE OUTCOMES FOR PATIENTS BY MATCHING THEM TO SUITABLE CLINICAL TRIALS. OUR NURSE NAVIGATORS ASSISTED 1,019 PATIENTS (UP 31% FROM 2020). OF THE 759 NEW PATIENTS ASSISTED (UP 31% FROM LAST YEAR), 21% ENTERED A TRIAL. WE WERE HONORED THAT A CTSC TEAM-AUTHORED ARTICLE, OVERCOMING BARRIERS TO CLINICAL TRIAL PARTICIPATION: OUTCOMES OF A NATIONAL CLINICAL TRIAL MATCHING AND NAVIGATION SERVICE FOR PATIENTS WITH A BLOOD CANCER, WAS PUBLISHED IN THE "JOURNAL OF CLINICAL ONCOLOGY, ONCOLOGY PRACTICE" IN MAY. OUTREACH TO UNDERSERVED GROUPS WE AUGMENTED EFFORTS TO EXPAND ACCESS TO LLS SERVICES AND RESOURCES BY BOLSTERING RELATIONS WITH COMMUNITY GROUPS AND LEADERS, NOTABLY IN THE AFRICAN AMERICAN AND LATINO COMMUNITIES, AND INCREASED OUR NUMBER OF BILINGUAL VOLUNTEERS. WE ALSO INCREASED ACCESSIBILITY OF OUR EDUCATION PROGRAMS TO RURAL PATIENTS AND FAMILIES VIA OUR VIRTUAL OFFERINGS. MOREOVER, WE EXPANDED PARTNERSHIPS WITH AFFINITY GROUPS INCLUDING: THE COALITION OF 100 BLACK WOMEN, THE MEXICAN CONSULATE'S VENTANILLA DE SALUD PROGRAM,AND PROMOTORES (VISION Y COMPROMISO). THE LLS MYELOMA LINK PROGRAM, LAUNCHED IN 2017, CONTINUED TO GAIN TRACTION. WE IMPROVED UNDERSTANDING OF TREATMENT OPTIONS BY PROVIDING IMPORTANT INFORMATION TO AFRICAN AMERICANS, WHO ARE TWICE AS LIKELY TO BE DIAGNOSED WITH MULTIPLE MYELOMA AS CAUCASIAN AMERICANS. IN 2021, LLS REACHED APPROXIMATELY 10,448 PEOPLE THROUGH MORE THAN 72 MYELOMA LINK EDUCATION AND OUTREACH ACTIVITIES IN 13 CITIES. EDUCATION AND PATIENT CONNECTIONS OUR VIRTUAL EDUCATION PROGRAMS PROVIDED BOTH PATIENTS AND FAMILIES, AS WELL AS HEALTH CARE PROFESSIONALS, ACCESS TO CONTENT INCLUDING BLOOD CANCER CONFERENCES, LOCAL EDUCATION PROGRAMS, NATIONAL WEBINARS, VIDEOS, LECTURES, AND PODCASTS. LLS'S HIGHLY VIEWED WEBSITE CONTINUES TO PROVIDE THE MOST UP TO DATE BLOOD CANCER INFORMATION INCLUDING ACCESS TO BLOGS, BOOKLETS, WORKBOOKS, FACT SHEETS AND MORE. IN ADDITION, NEARLY 1,000 CANCER PATIENTS WERE PROVIDED WITH PERSONALIZED NUTRITION CONSULTATIONS BY LLS'S REGISTERED DIETITIAN. OUR PATIENT & COMMUNITY OUTREACH TEAM CONTINUED TO BRING PATIENTS TOGETHER VIA ONLINE LOCAL SUPPORT GROUPS AND CHATS. THE PATTI ROBINSON KAUFMANN FIRST CONNECTION PROGRAM MATCHED NEARLY 1,800 PATIENTS (UP 5% FROM 2020) WITH TRAINED VOLUNTEERS FACING THE SAME DISEASE, HELPING TO AVERT PANDEMIC-RELATED ISOLATION. IN ADDITION, MEMBERSHIP IN LLS COMMUNITY-OUR ONLINE SOCIAL NETWORK-INCREASED 23% OVER 2020. | Desc |
Prog Srvc Accom Acty Other ProgSrvcAccomActyOtherGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Expense | $9,280,825 | ExpenseAmt |
| Desc | D) PROFESSIONAL EDUCATION: LLS SERVES THE EDUCATIONAL NEEDS OF THE MEDICAL AND RESEARCH COMMUNITY THROUGH A NUMBER OF PROFESSIONAL EDUCATION SYMPOSIA OFFERED THROUGHOUT THE YEAR. THE EDUCATIONAL PROGRAM OFFERS VARYING FORMATS TO FACILITATE THE EXCHANGE OF INFORMATION AND IDEAS ON THE NEWEST DEVELOPMENTS IN CANCER RESEARCH AND TREATMENT. UPCOMING AND ARCHIVED CE/CME PROGRAMS ARE AVAILABLE AT WWW.LLS.ORG/CE. IN FY 2021: -LLS PROVIDED 14 CME/CE-GRANTING VIRTUAL EDUCATIONAL PROGRAMS, WITH 2,345 HEALTHCARE PROFESSIONALS IN ATTENDANCE. --THERE WERE 44,790 PAGE VIEWS FOR ARCHIVED WEB PROGRAMS, 25,541 VIRTUAL LECTURE VIEWS AND 14,107 PODCAST DOWNLOADS. | Desc |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Other Prog Srvc Expense | $9,280,825 | TotalOtherProgSrvcExpenseAmt |
| Total Program Service Expenses | $255,022,127 | TotalProgramServiceExpensesAmt |
| Described In Section501c3 | Yes (true) | DescribedInSection501c3Ind |
| Schedule B Required | Yes (true) | ScheduleBRequiredInd |
| Political Campaign Acty | false | PoliticalCampaignActyInd |
| Lobbying Activities | Yes (true) | LobbyingActivitiesInd |
| Subject To Proxy Tax | false | SubjectToProxyTaxInd |
| Donor Advised Fund | false | DonorAdvisedFundInd |
| Conservation Easements | false | ConservationEasementsInd |
| Collections Of Art | Yes (true) | CollectionsOfArtInd |
| Credit Counseling | false | CreditCounselingInd |
| Donor Rstr Or Quasi Endowments | Yes (true) | DonorRstrOrQuasiEndowmentsInd |
| Report Land Building Equipment | Yes (true) | ReportLandBuildingEquipmentInd |
| Report Investments Other Sec | false | ReportInvestmentsOtherSecInd |
| Report Program Related Invst | false | ReportProgramRelatedInvstInd |
| Report Other Assets | false | ReportOtherAssetsInd |
| Report Other Liabilities | false | ReportOtherLiabilitiesInd |
| Include FIN48 Footnote | Yes (true) | IncludeFIN48FootnoteInd |
| Independent Audit Fincl Stmt | false | IndependentAuditFinclStmtInd |
| Consolidated Audit Fincl Stmt | Yes (true) | ConsolidatedAuditFinclStmtInd |
| School Operating | false | SchoolOperatingInd |
| Foreign Office | Yes (true) | ForeignOfficeInd |
| Foreign Activities | Yes (true) | ForeignActivitiesInd |
| More Than5000 K To Org | Yes (true) | MoreThan5000KToOrgInd |
| More Than5000 K To Individuals | false | MoreThan5000KToIndividualsInd |
| Professional Fundraising | Yes (true) | ProfessionalFundraisingInd |
| Fundraising Activities | Yes (true) | FundraisingActivitiesInd |
| Gaming Activities | Yes (true) | GamingActivitiesInd |
| Operate Hospital | false | OperateHospitalInd |
| Grants To Organizations | Yes (true) | GrantsToOrganizationsInd |
| Grants To Individuals | Yes (true) | GrantsToIndividualsInd |
| Schedule J Required | Yes (true) | ScheduleJRequiredInd |
| Tax Exempt Bonds | false | TaxExemptBondsInd |
| Engaged In Excess Benefit Trans | false | EngagedInExcessBenefitTransInd |
| PY Excess Benefit Trans | false | PYExcessBenefitTransInd |
| Loan Outstanding | false | LoanOutstandingInd |
| Grant To Related Person | false | GrantToRelatedPersonInd |
| Business Rln With Org Mem | false | BusinessRlnWithOrgMemInd |
| Business Rln With Fam Mem | false | BusinessRlnWithFamMemInd |
| Business Rln With35 Ctrl Ent | false | BusinessRlnWith35CtrlEntInd |
| Deductible Non Cash Contri | Yes (true) | DeductibleNonCashContriInd |
| Deductible Art Contribution | false | DeductibleArtContributionInd |
| Terminate Operations | false | TerminateOperationsInd |
| Partial Liquidation | false | PartialLiquidationInd |
| Disregarded Entity | Yes (true) | DisregardedEntityInd |
| Related Entity | Yes (true) | RelatedEntityInd |
| Related Organization Ctrl Ent | Yes (true) | RelatedOrganizationCtrlEntInd |
| Transaction With Control Ent | Yes (true) | TransactionWithControlEntInd |
| Trnsfr Exmpt Non Chrtbl Rltd Org | false | TrnsfrExmptNonChrtblRltdOrgInd |
| Activities Conducted Prtshp | false | ActivitiesConductedPrtshpInd |
| Schedule O Required | Yes (true) | ScheduleORequiredInd |
| IRP Document | 267 | IRPDocumentCnt |
| IRP Document W2 G | 0 | IRPDocumentW2GCnt |
| Backup Wthld Compliance | Yes (true) | BackupWthldComplianceInd |
| Employee | 1300 | EmployeeCnt |
| Employment Tax Returns Filed | Yes (true) | EmploymentTaxReturnsFiledInd |
| Unrelated Bus Incm Over Limit | false | UnrelatedBusIncmOverLimitInd |
| Foreign Financial Account | Yes (true) | ForeignFinancialAccountInd |
| Foreign Country | CA | ForeignCountryCd |
| Prohibited Tax Shelter Trans | false | ProhibitedTaxShelterTransInd |
| Taxable Party Notification | false | TaxablePartyNotificationInd |
| Nondeductible Contributions | false | NondeductibleContributionsInd |
| Quid Pro Quo Contributions | Yes (true) | QuidProQuoContributionsInd |
| Quid Pro Quo Contri Discl | Yes (true) | QuidProQuoContriDisclInd |
| Form8282 Property Disposed Of | false | Form8282PropertyDisposedOfInd |
| Rcv Fnds To Pay Prsnl Bnft Cntrct | false | RcvFndsToPayPrsnlBnftCntrctInd |
| Pay Premiums Prsnl Bnft Cntrct | false | PayPremiumsPrsnlBnftCntrctInd |
| Indoor Tanning Services | false | IndoorTanningServicesInd |
| Subj To Tax Rmnrtn Ex Prcht Pymt | false | SubjToTaxRmnrtnExPrchtPymtInd |
| Subject To Excs Tax Net Invst Inc | false | SubjectToExcsTaxNetInvstIncInd |
| Info In Schedule O Part VI | Yes (X) | InfoInScheduleOPartVIInd |
| Governing Body Voting Members | 19 | GoverningBodyVotingMembersCnt |
| Independent Voting Member | 19 | IndependentVotingMemberCnt |
| Family Or Business Rln | false | FamilyOrBusinessRlnInd |
| Delegation Of Mgmt Duties | false | DelegationOfMgmtDutiesInd |
| Change To Org Documents | false | ChangeToOrgDocumentsInd |
| Material Diversion Or Misuse | false | MaterialDiversionOrMisuseInd |
| Members Or Stockholders | false | MembersOrStockholdersInd |
| Election Of Board Members | false | ElectionOfBoardMembersInd |
| Decisions Subject To Approva | false | DecisionsSubjectToApprovaInd |
| Minutes Of Governing Body | Yes (true) | MinutesOfGoverningBodyInd |
| Minutes Of Committees | Yes (true) | MinutesOfCommitteesInd |
| Officer Mailing Address | false | OfficerMailingAddressInd |
| Local Chapters | Yes (true) | LocalChaptersInd |
| Policies Reference Chapters | Yes (true) | PoliciesReferenceChaptersInd |
| Form990 Provided To Gvrn Body | Yes (true) | Form990ProvidedToGvrnBodyInd |
| Conflict Of Interest Policy | Yes (true) | ConflictOfInterestPolicyInd |
| Annual Disclosure Covered Prsn | Yes (true) | AnnualDisclosureCoveredPrsnInd |
| Regular Monitoring Enfrc | Yes (true) | RegularMonitoringEnfrcInd |
| Whistleblower Policy | Yes (true) | WhistleblowerPolicyInd |
| Document Retention Policy | Yes (true) | DocumentRetentionPolicyInd |
| Compensation Process CEO | Yes (true) | CompensationProcessCEOInd |
| Compensation Process Other | Yes (true) | CompensationProcessOtherInd |
| Investment In Joint Venture | false | InvestmentInJointVentureInd |
| States Where Copy Of Return Is Fld | AK | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | AL | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | AR | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | AZ | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | CA | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | CO | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | CT | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | DE | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | DC | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | FL | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | GA | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | HI | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | ID | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | IL | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | IN | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | KS | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | KY | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | LA | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | MA | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | MD | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | ME | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | MI | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | MN | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | MO | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | MS | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | NH | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | NJ | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | NM | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | NE | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | NY | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | OH | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | OK | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | OR | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | PA | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | PR | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | RI | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | SC | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | TN | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | UT | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | VA | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | WA | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | WI | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | WV | StatesWhereCopyOfReturnIsFldCd |
| Own Website | Yes (X) | OwnWebsiteInd |
| Upon Request | Yes (X) | UponRequestInd |
Books In Care Of Detail BooksInCareOfDetail
| Field | Value | IRS element (for citing) |
|---|---|---|
| Person | GORDON MILLER JR | PersonNm |
| Phone | 9148218935 | PhoneNum |
US Address USAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 3 INTERNATIONAL DRIVE | AddressLine1Txt |
| City | RYE BROOK | CityNm |
| State Abbreviation | NY | StateAbbreviationCd |
| ZIP | 10573 | ZIPCd |
Form990 Part VII Section A Form990PartVIISectionAGrp (29 entries)
| TitleTitleTxt | Average Hours Per WeekAverageHoursPerWeekRt | Average Hours Per Week Rltd OrgAverageHoursPerWeekRltdOrgRt | OfficerOfficerInd | Reportable Comp From OrgReportableCompFromOrgAmt | Reportable Comp From Rltd OrgReportableCompFromRltdOrgAmt | Other CompensationOtherCompensationAmt | Highest Compensated EmployeeHighestCompensatedEmployeeInd | Former Ofcr Director TrusteeFormerOfcrDirectorTrusteeInd | Individual Trustee Or DirectorIndividualTrusteeOrDirectorInd |
|---|---|---|---|---|---|---|---|---|---|
| LOUIS J DEGENNARO PHD | |||||||||
| PRESIDENT & | 40.00 | 1.00 | Yes (X) | $950,516 | $0 | $41,258 | |||
| GWEN NICHOLS MD | |||||||||
| EVP CHIEF ME | 40.00 | Yes (X) | $406,230 | $0 | $27,197 | ||||
| TROY DUNMIRE - START 1132020 | |||||||||
| EVP CHIEF OP | 40.00 | Yes (X) | $408,554 | $0 | $20,814 | ||||
| VANESSA WHITE | |||||||||
| SVP CHIEF AD | 40.00 | $355,467 | $0 | $26,217 | Yes (X) | ||||
| LEE M GREENBERGER | |||||||||
| SVP CHIEF SC | 40.00 | $325,543 | $0 | $42,366 | Yes (X) | ||||
| KATHY GRIESENBECK - END 7312020 | |||||||||
| EVP CHIEF RE | 40.00 | $347,706 | $0 | $17,857 | Yes (X) | ||||
| COKER POWELL | |||||||||
| EVP PROD CAM | 40.00 | $320,245 | $0 | $44,460 | Yes (X) | ||||
| GORDON MILLER JR | |||||||||
| EVP CHIEF FI | 40.00 | 1.00 | Yes (X) | $321,228 | $0 | $36,312 | |||
| MARGO LUCERO - END 7312020 | |||||||||
| EVP CORP PAR | 40.00 | $336,366 | $0 | $19,808 | Yes (X) | ||||
| ROSEMARIE ALOFFREDO - END 3312019 | |||||||||
| CHIEF FIN OF | 40.00 | $177,503 | $0 | $0 | Yes (X) | ||||
| ALESSANDRA TOCCO - START 712020 | |||||||||
| BOD MEMBER | 4.00 | $0 | $0 | $0 | Yes (X) | ||||
| FREDA WANG - START 712020 | |||||||||
| BOD MEMBER | 4.00 | $0 | $0 | $0 | Yes (X) | ||||
| RICH BAGGER - START 712020 | |||||||||
| BOD MEMBER | 4.00 | $0 | $0 | $0 | Yes (X) | ||||
| RICHARD RENDINA - START 712020 | |||||||||
| BOD MEMBER | 4.00 | $0 | $0 | $0 | Yes (X) | ||||
| MICHELE CAMERON | |||||||||
| BOD MEMBER | 4.00 | $0 | $0 | $0 | Yes (X) | ||||
| RALPH E LAWSON FHFMA CPA | |||||||||
| CHAIRMAN | 4.00 | Yes (X) | $0 | $0 | $0 | Yes (X) | |||
| RUBEN MESA MD FACP | |||||||||
| AT LARGE | 4.00 | Yes (X) | $0 | $0 | $0 | Yes (X) | |||
| JOHN GREENE | |||||||||
| BOD MEMBER | 4.00 | $0 | $0 | $0 | Yes (X) | ||||
| FRANCIE HELLER | |||||||||
| BOD MEMBER | 4.00 | $0 | $0 | $0 | Yes (X) | ||||
| CASEY CUNNINGHAM MD | |||||||||
| BOD MEMBER | 4.00 | $0 | $0 | $0 | Yes (X) | ||||
| CHRISTOPHER FLOWERS MD | |||||||||
| BOD MEMBER | 4.00 | $0 | $0 | $0 | Yes (X) | ||||
| JANICE GABRILOVE MD | |||||||||
| BOD MEMBER | 4.00 | $0 | $0 | $0 | Yes (X) | ||||
| RENZO CANETTA MD | |||||||||
| BOD MEMBER | 4.00 | $0 | $0 | $0 | Yes (X) | ||||
| KATHLEEN MERIWETHER | |||||||||
| SECRETARY/TR | 4.00 | Yes (X) | $0 | $0 | $0 | Yes (X) | |||
| LYNNE O'BRIEN | |||||||||
| BOD MEMBER | 4.00 | $0 | $0 | $0 | Yes (X) | ||||
| MARLA PERSKY | |||||||||
| BOD MEMBER | 4.00 | $0 | $0 | $0 | Yes (X) | ||||
| ROBERT ROSEN | |||||||||
| BOD MEMBER | 4.00 | $0 | $0 | $0 | Yes (X) | ||||
| JEFF SACHS | |||||||||
| VICE CHAIR | 4.00 | Yes (X) | $0 | $0 | $0 | Yes (X) | |||
| BART SICHEL | |||||||||
| BOD MEMBER | 4.00 | $0 | $0 | $0 | Yes (X) | ||||
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Reportable Comp From Org | $3,949,358 | TotalReportableCompFromOrgAmt |
| Total Other Compensation | $276,289 | TotalOtherCompensationAmt |
| Indiv Rcvd Greater Than100 K | 236 | IndivRcvdGreaterThan100KCnt |
| Former Ofcr Employees Listed | Yes (true) | FormerOfcrEmployeesListedInd |
| Total Comp Greater Than150 K | Yes (true) | TotalCompGreaterThan150KInd |
| Compensation From Other Srcs | false | CompensationFromOtherSrcsInd |
Contractor Compensation ContractorCompensationGrp (5 entries)
| Address Line1ContractorAddress/USAddress/AddressLine1Txt | CityContractorAddress/USAddress/CityNm | State AbbreviationContractorAddress/USAddress/StateAbbreviationCd | ZIPContractorAddress/USAddress/ZIPCd | ServicesServicesDesc | CompensationCompensationAmt |
|---|---|---|---|---|---|
| PATIENT ADVOCACY FOUNDATION | |||||
| 421 BUTLER FARM RD | HAMPTON | VA | 23666 | PAT ASSIST PROC | $7,853,107 |
| SYNEOS HEALTH LLC | |||||
| 75 REMITTANCE DRIVE SUITE 3160 | CHICAGO | IL | 606753160 | CLINICAL TRIAL | $5,656,214 |
| RESOURCE ONE | |||||
| 2900 EAST APACHE STREET | TULSA | OK | 74110 | DIRECT MARKETIN | $4,630,228 |
| MERKLE | |||||
| 29432 NETWORK PLACE | CHICAGO | IL | 606731294 | MARKETING | $2,513,376 |
| 1 HACKER WAY | MENLO PARK | CA | 94025 | ADVERTISING | $2,282,901 |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Cntrct Rcvd Greater Than100 K | 141 | CntrctRcvdGreaterThan100KCnt |
| Info In Schedule O Part VIII | Yes (X) | InfoInScheduleOPartVIIIInd |
| Federated Campaigns | $2,694,841 | FederatedCampaignsAmt |
| Fundraising | $160,127,233 | FundraisingAmt |
| All Other Contributions | $278,495,420 | AllOtherContributionsAmt |
| Noncash Contributions | $1,784,277 | NoncashContributionsAmt |
| Total Contributions | $441,317,494 | TotalContributionsAmt |
Program Service Revenue ProgramServiceRevenueGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Desc | SERVICE REVENUE | Desc |
| Business | 810000 | BusinessCd |
| Total Revenue Column | $12,281,240 | TotalRevenueColumnAmt |
| Related Or Exempt Func Income | $12,281,240 | RelatedOrExemptFuncIncomeAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Program Service Revenue | $12,281,240 | TotalProgramServiceRevenueAmt |
Investment Income InvestmentIncomeGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $4,332,782 | TotalRevenueColumnAmt |
| Exclusion | $4,332,782 | ExclusionAmt |
Royalties Revenue RoyaltiesRevenueGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $12,544,341 | TotalRevenueColumnAmt |
| Exclusion | $12,544,341 | ExclusionAmt |
Gross Amount Sales Assets GrossAmountSalesAssetsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Securities | $63,571,033 | SecuritiesAmt |
Less Cost Oth Basis Sales Expnss LessCostOthBasisSalesExpnssGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Securities | $55,605,491 | SecuritiesAmt |
Gain Or Loss GainOrLossGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Securities | $7,965,542 | SecuritiesAmt |
Net Gain Or Loss Investments NetGainOrLossInvestmentsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $7,965,542 | TotalRevenueColumnAmt |
| Exclusion | $7,965,542 | ExclusionAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Fundraising Gross Income | $4,820,136 | FundraisingGrossIncomeAmt |
| Contri Rpt Fundraising Event | $160,127,233 | ContriRptFundraisingEventAmt |
| Fundraising Direct Expenses | $5,673,129 | FundraisingDirectExpensesAmt |
Net Incm From Fundraising Evt NetIncmFromFundraisingEvtGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | -$852,993 | TotalRevenueColumnAmt |
| Exclusion | -$852,993 | ExclusionAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Gaming Gross Income | $77,510 | GamingGrossIncomeAmt |
| Gaming Direct Expenses | $2,200 | GamingDirectExpensesAmt |
Net Income From Gaming NetIncomeFromGamingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $75,310 | TotalRevenueColumnAmt |
| Exclusion | $75,310 | ExclusionAmt |
Total Revenue TotalRevenueGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $477,663,716 | TotalRevenueColumnAmt |
| Related Or Exempt Func Income | $12,281,240 | RelatedOrExemptFuncIncomeAmt |
| Exclusion | $24,064,982 | ExclusionAmt |
Grants To Domestic Orgs GrantsToDomesticOrgsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $29,137,705 | TotalAmt |
| Program Services | $29,137,705 | ProgramServicesAmt |
Grants To Domestic Individuals GrantsToDomesticIndividualsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $118,625,934 | TotalAmt |
| Program Services | $118,625,934 | ProgramServicesAmt |
Foreign Grants ForeignGrantsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $4,790,635 | TotalAmt |
| Program Services | $4,790,635 | ProgramServicesAmt |
Comp Current Ofcr Directors CompCurrentOfcrDirectorsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $1,994,372 | TotalAmt |
| Program Services | $697,169 | ProgramServicesAmt |
| Management And General | $1,015,200 | ManagementAndGeneralAmt |
| Fundraising | $282,003 | FundraisingAmt |
Other Salaries And Wages OtherSalariesAndWagesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $89,968,243 | TotalAmt |
| Program Services | $45,167,324 | ProgramServicesAmt |
| Management And General | $21,529,702 | ManagementAndGeneralAmt |
| Fundraising | $23,271,217 | FundraisingAmt |
Pension Plan Contributions PensionPlanContributionsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $3,091,830 | TotalAmt |
| Program Services | $1,440,530 | ProgramServicesAmt |
| Management And General | $863,958 | ManagementAndGeneralAmt |
| Fundraising | $787,342 | FundraisingAmt |
Other Employee Benefits OtherEmployeeBenefitsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $11,667,753 | TotalAmt |
| Program Services | $5,462,304 | ProgramServicesAmt |
| Management And General | $3,222,357 | ManagementAndGeneralAmt |
| Fundraising | $2,983,092 | FundraisingAmt |
Payroll Taxes PayrollTaxesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $7,026,699 | TotalAmt |
| Program Services | $3,273,845 | ProgramServicesAmt |
| Management And General | $1,963,488 | ManagementAndGeneralAmt |
| Fundraising | $1,789,366 | FundraisingAmt |
Fees For Services Legal FeesForServicesLegalGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $2,681,155 | TotalAmt |
| Program Services | $1,608,693 | ProgramServicesAmt |
| Management And General | $723,912 | ManagementAndGeneralAmt |
| Fundraising | $348,550 | FundraisingAmt |
Fees For Services Accounting FeesForServicesAccountingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $441,164 | TotalAmt |
| Management And General | $441,164 | ManagementAndGeneralAmt |
Fees For Services Lobbying FeesForServicesLobbyingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $1,462,660 | TotalAmt |
| Program Services | $1,462,660 | ProgramServicesAmt |
Fees For Services Prof Fundraising FeesForServicesProfFundraising
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $9,126,288 | TotalAmt |
| Fundraising | $9,126,288 | FundraisingAmt |
Fees For Srvc Invst Mgmnt Fees FeesForSrvcInvstMgmntFeesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $653,745 | TotalAmt |
| Program Services | $485,260 | ProgramServicesAmt |
| Management And General | $79,871 | ManagementAndGeneralAmt |
| Fundraising | $88,614 | FundraisingAmt |
Fees For Services Other FeesForServicesOtherGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $22,042,230 | TotalAmt |
| Program Services | $15,988,647 | ProgramServicesAmt |
| Management And General | $3,029,423 | ManagementAndGeneralAmt |
| Fundraising | $3,024,160 | FundraisingAmt |
Advertising AdvertisingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $7,062,645 | TotalAmt |
| Program Services | $4,121,254 | ProgramServicesAmt |
| Management And General | $609,605 | ManagementAndGeneralAmt |
| Fundraising | $2,331,786 | FundraisingAmt |
Office Expenses OfficeExpensesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $14,763,355 | TotalAmt |
| Program Services | $8,657,502 | ProgramServicesAmt |
| Management And General | $1,429,009 | ManagementAndGeneralAmt |
| Fundraising | $4,676,844 | FundraisingAmt |
Information Technology InformationTechnologyGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $12,131,350 | TotalAmt |
| Program Services | $914,704 | ProgramServicesAmt |
| Management And General | $9,011,167 | ManagementAndGeneralAmt |
| Fundraising | $2,205,479 | FundraisingAmt |
Occupancy OccupancyGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $8,495,355 | TotalAmt |
| Program Services | $4,153,398 | ProgramServicesAmt |
| Management And General | $1,624,264 | ManagementAndGeneralAmt |
| Fundraising | $2,717,693 | FundraisingAmt |
Travel TravelGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $23,191 | TotalAmt |
| Program Services | $487 | ProgramServicesAmt |
| Management And General | $8,017 | ManagementAndGeneralAmt |
| Fundraising | $14,687 | FundraisingAmt |
Depreciation Depletion DepreciationDepletionGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $3,476,787 | TotalAmt |
| Program Services | $345,544 | ProgramServicesAmt |
| Management And General | $2,860,942 | ManagementAndGeneralAmt |
| Fundraising | $270,301 | FundraisingAmt |
Insurance InsuranceGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $866,139 | TotalAmt |
| Program Services | $54,649 | ProgramServicesAmt |
| Management And General | $813,298 | ManagementAndGeneralAmt |
| Fundraising | -$1,808 | FundraisingAmt |
Other Expenses OtherExpensesGrp (2 entries)
| DescDesc | TotalTotalAmt | Program ServicesProgramServicesAmt | Management And GeneralManagementAndGeneralAmt | FundraisingFundraisingAmt |
|---|---|---|---|---|
| RESEARCH AND DEVELOPMENT | $6,877,888 | $6,877,888 | ||
| MISCELLANEOUS | $3,441,056 | $1,755,995 | $745,711 | $939,350 |
Total Functional Expenses TotalFunctionalExpensesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $359,848,179 | TotalAmt |
| Program Services | $255,022,127 | ProgramServicesAmt |
| Management And General | $49,971,088 | ManagementAndGeneralAmt |
| Fundraising | $54,854,964 | FundraisingAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Joint Costs | Yes (X) | JointCostsInd |
Total Joint Costs TotalJointCostsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $15,929,798 | TotalAmt |
| Program Services | $10,677,326 | ProgramServicesAmt |
| Fundraising | $5,252,472 | FundraisingAmt |
Cash Non Interest Bearing CashNonInterestBearingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $27,772,961 | BOYAmt |
| EOY | $17,101,591 | EOYAmt |
Savings And Temp Cash Invst SavingsAndTempCashInvstGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $363,331,593 | BOYAmt |
| EOY | $118,564,418 | EOYAmt |
Pledges And Grants Receivable PledgesAndGrantsReceivableGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $24,021,989 | BOYAmt |
| EOY | $13,531,687 | EOYAmt |
Prepaid Expenses Defrd Charges PrepaidExpensesDefrdChargesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $3,815,548 | BOYAmt |
| EOY | $3,702,570 | EOYAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Land Bldg Equip Cost Or Other Bss | $18,569,968 | LandBldgEquipCostOrOtherBssAmt |
| Land Bldg Equip Accum Deprec | $7,821,920 | LandBldgEquipAccumDeprecAmt |
Land Bldg Equip Basis Net LandBldgEquipBasisNetGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $9,345,892 | BOYAmt |
| EOY | $10,748,048 | EOYAmt |
Investments Pub Traded Sec InvestmentsPubTradedSecGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $138,900,813 | BOYAmt |
| EOY | $552,134,623 | EOYAmt |
Investments Other Securities InvestmentsOtherSecuritiesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $10,426,610 | BOYAmt |
| EOY | $20,423,995 | EOYAmt |
Investments Program Related InvestmentsProgramRelatedGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $4,062,204 | BOYAmt |
| EOY | $7,406,850 | EOYAmt |
Total Assets TotalAssetsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $581,677,610 | BOYAmt |
| EOY | $743,613,782 | EOYAmt |
Accounts Payable Accr Expnss AccountsPayableAccrExpnssGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $23,457,200 | BOYAmt |
| EOY | $28,917,585 | EOYAmt |
Grants Payable GrantsPayableGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $179,469,755 | BOYAmt |
| EOY | $188,608,360 | EOYAmt |
Deferred Revenue DeferredRevenueGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $12,628,217 | BOYAmt |
| EOY | $12,315,339 | EOYAmt |
Total Liabilities TotalLiabilitiesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $215,555,172 | BOYAmt |
| EOY | $229,841,284 | EOYAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Organization Follows FASB117 | Yes (X) | OrganizationFollowsFASB117Ind |
No Donor Restriction Net Assets NoDonorRestrictionNetAssetsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $249,719,310 | BOYAmt |
| EOY | $328,718,773 | EOYAmt |
Donor Restriction Net Assets DonorRestrictionNetAssetsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $116,403,128 | BOYAmt |
| EOY | $185,053,725 | EOYAmt |
Total Net Assets Fund Balance TotalNetAssetsFundBalanceGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $366,122,438 | BOYAmt |
| EOY | $513,772,498 | EOYAmt |
Tot Liab Net Assets Fund Balance TotLiabNetAssetsFundBalanceGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $581,677,610 | BOYAmt |
| EOY | $743,613,782 | EOYAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Info In Schedule O Part XI | Yes (X) | InfoInScheduleOPartXIInd |
| Reconcilation Revenue Expnss | $117,815,537 | ReconcilationRevenueExpnssAmt |
| Net Unrlzd Gains Losses Invst | $29,836,577 | NetUnrlzdGainsLossesInvstAmt |
| Other Changes In Net Assets | -$2,054 | OtherChangesInNetAssetsAmt |
| Method Of Accounting Accrual | Yes (X) | MethodOfAccountingAccrualInd |
| Accountant Compile Or Review | false | AccountantCompileOrReviewInd |
| FS Audited | Yes (true) | FSAuditedInd |
FS Audited Basis FSAuditedBasisGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Consolidated Basis Fincl Stmt | Yes (X) | ConsolidatedBasisFinclStmtInd |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Audit Committee | Yes (true) | AuditCommitteeInd |
| Federal Grant Audit Required | false | FederalGrantAuditRequiredInd |
Schedule A IRS990ScheduleA
| Field | Value | IRS element (for citing) |
|---|---|---|
| Public Organization170 | Yes (X) | PublicOrganization170Ind |
Gifts Grants Contri Rcvd170 GiftsGrantsContriRcvd170Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Tax Year Minus4 Years | $314,912,814 | CurrentTaxYearMinus4YearsAmt |
| Current Tax Year Minus3 Years | $419,570,497 | CurrentTaxYearMinus3YearsAmt |
| Current Tax Year Minus2 Years | $372,750,094 | CurrentTaxYearMinus2YearsAmt |
| Current Tax Year Minus1 Year | $427,419,530 | CurrentTaxYearMinus1YearAmt |
| Current Tax Year | $441,317,494 | CurrentTaxYearAmt |
| Total | $1,975,970,429 | TotalAmt |
Total Calendar Year170 TotalCalendarYear170Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Tax Year Minus4 Years | $314,912,814 | CurrentTaxYearMinus4YearsAmt |
| Current Tax Year Minus3 Years | $419,570,497 | CurrentTaxYearMinus3YearsAmt |
| Current Tax Year Minus2 Years | $372,750,094 | CurrentTaxYearMinus2YearsAmt |
| Current Tax Year Minus1 Year | $427,419,530 | CurrentTaxYearMinus1YearAmt |
| Current Tax Year | $441,317,494 | CurrentTaxYearAmt |
| Total | $1,975,970,429 | TotalAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Substantial Contributors Tot | $515,721,732 | SubstantialContributorsTotAmt |
| Public Support Total170 | $1,460,248,697 | PublicSupportTotal170Amt |
Gross Investment Income170 GrossInvestmentIncome170Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Tax Year Minus4 Years | $7,018,822 | CurrentTaxYearMinus4YearsAmt |
| Current Tax Year Minus3 Years | $8,235,985 | CurrentTaxYearMinus3YearsAmt |
| Current Tax Year Minus2 Years | $11,830,162 | CurrentTaxYearMinus2YearsAmt |
| Current Tax Year Minus1 Year | $29,082,073 | CurrentTaxYearMinus1YearAmt |
| Current Tax Year | $16,877,123 | CurrentTaxYearAmt |
| Total | $73,044,165 | TotalAmt |
Other Income170 OtherIncome170Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Tax Year Minus4 Years | $25,439,044 | CurrentTaxYearMinus4YearsAmt |
| Current Tax Year Minus3 Years | $70,000 | CurrentTaxYearMinus3YearsAmt |
| Total | $25,509,044 | TotalAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Support | $2,074,523,638 | TotalSupportAmt |
| Gross Receipts Rltd Activities | $90,794,633 | GrossReceiptsRltdActivitiesAmt |
| Public Support CY170 | 0.70390 | PublicSupportCY170Pct |
| Public Support PY170 | 0.75400 | PublicSupportPY170Pct |
| Thirty Thr Pct Suprt Tests CY170 | Yes (X) | ThirtyThrPctSuprtTestsCY170Ind |
Form990 Schedule A Part VI Form990ScheduleAPartVIGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Form And Line Reference | PART II, LINE 10 | FormAndLineReferenceDesc |
| Explanation | OTHER MISC. REVENUE (YR 2015-2017) 188,848 TAP CONTRACTUAL RETURN (YR 2016) 25,320,196 | ExplanationTxt |
Schedule B IRS990ScheduleB
Contributor Information ContributorInformationGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Contributor | RESTRICTED | ContributorNum |
Contributor Business Name ContributorBusinessName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | RESTRICTED | BusinessNameLine1 |
Contributor US Address ContributorUSAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | RESTRICTED | AddressLine1 |
| Address Line2 | RESTRICTED | AddressLine2 |
| City | RESTRICTED | City |
| State | RESTRICTED | State |
| ZIP Code | RESTRICTED | ZIPCode |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Contributions | RESTRICTED | TotalContributionsAmt |
Schedule C IRS990ScheduleC
| Field | Value | IRS element (for citing) |
|---|---|---|
| Volunteers | Yes (true) | VolunteersInd |
| Paid Staff Or Management | Yes (true) | PaidStaffOrManagementInd |
| Media Advertisements | Yes (true) | MediaAdvertisementsInd |
| Media Advertisements | $66,059 | MediaAdvertisementsAmt |
| Mailings Members | false | MailingsMembersInd |
| Publications Or Broadcast | Yes (true) | PublicationsOrBroadcastInd |
| Publications Or Broadcast | $105,098 | PublicationsOrBroadcastAmt |
| Grants Other Organizations | false | GrantsOtherOrganizationsInd |
| Direct Contact Legislators | Yes (true) | DirectContactLegislatorsInd |
| Direct Contact Legislators | $308,666 | DirectContactLegislatorsAmt |
| Rallies Demonstrations | Yes (true) | RalliesDemonstrationsInd |
| Rallies Demonstrations | $110,404 | RalliesDemonstrationsAmt |
| Other Activities | Yes (true) | OtherActivitiesInd |
| Other Activities | $1,261,825 | OtherActivitiesAmt |
| Total Lobbying Expenditures | $1,852,052 | TotalLobbyingExpendituresAmt |
| Not Described Section501c3 | false | NotDescribedSection501c3Ind |
Supplemental Information Detail SupplementalInformationDetail
| Field | Value | IRS element (for citing) |
|---|---|---|
| Form And Line Reference | SCHEDULE C, PART II-B, LINE 1 | FormAndLineReferenceDesc |
| Explanation | LLS IS A MEMBER OF A NUMBER OF COALITIONS AND MEMBERSHIPS INCLUDING FRIENDS OF CANCER RESEARCH, ONE VOICE AGAINST CANCER, NATIONAL HEALTH COUNCIL, THE CANCER LEADERSHIP COUNCIL, AMERICAN CHILDHOOD CANCER ORGANIZATION, PUBLIC AFFAIRS COUNCIL, PATIENT QUALITY OF LIFE COALITION, DEFENSE HEALTH RESEARCH CONSORTIUM, AND THE STATE ACCESS TO INNOVATIVE MEDICINES COALITION. LLS PARTNERS WITH LOBBYING FIRMS WHO WORK WITH OUR PUBLIC POLICY STAFF TO CARRY OUT OUR LOBBYING OBJECTIVES. LLS MOBILIZES PATIENT-ADVOCATES AND VOLUNTEERS TO ENGAGE WITH THEIR FEDERAL AND STATE LEGISLATORS THROUGH DIGITAL ADVOCACY - SENDING LETTERS; SHARING THEIR PERSONAL STORIES; SIGNING PETITIONS; AND ENCOURAGING THEIR LEGISLATORS TO SUPPORT LLS' POLICY PRIORITIES. IN CONJUNCTION WITH LLS EMPLOYEES, PATIENT-ADVOCATES ALSO VISIT THEIR LEGISLATORS IN THEIR LOCAL OFFICES, IN WASHINGTON, DC AND IN STATE CAPITOLS TO FURTHER LLS'S POLICY AGENDA. | ExplanationTxt |
Schedule D IRS990ScheduleD
| Field | Value | IRS element (for citing) |
|---|---|---|
| Collection Used Pub Exhibition | Yes (X) | CollectionUsedPubExhibitionInd |
| Solicited Assets Sale | false | SolicitedAssetsSaleInd |
CY Endwmt Fund CYEndwmtFundGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Beginning Year Balance | $5,902,791 | BeginningYearBalanceAmt |
| Contributions | $1,650 | ContributionsAmt |
| Investment Earnings Or Losses | $1,726,314 | InvestmentEarningsOrLossesAmt |
| Grants Or Scholarships | -$236,177 | GrantsOrScholarshipsAmt |
| Administrative Expenses | -$13,118 | AdministrativeExpensesAmt |
| End Year Balance | $7,381,460 | EndYearBalanceAmt |
CY Minus1 Yr Endwmt Fund CYMinus1YrEndwmtFundGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Beginning Year Balance | $6,168,319 | BeginningYearBalanceAmt |
| Investment Earnings Or Losses | -$8,812 | InvestmentEarningsOrLossesAmt |
| Grants Or Scholarships | -$246,718 | GrantsOrScholarshipsAmt |
| Administrative Expenses | -$9,998 | AdministrativeExpensesAmt |
| End Year Balance | $5,902,791 | EndYearBalanceAmt |
CY Minus2 Yr Endwmt Fund CYMinus2YrEndwmtFundGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Beginning Year Balance | $6,192,807 | BeginningYearBalanceAmt |
| Investment Earnings Or Losses | $292,934 | InvestmentEarningsOrLossesAmt |
| Grants Or Scholarships | -$304,999 | GrantsOrScholarshipsAmt |
| Administrative Expenses | -$12,423 | AdministrativeExpensesAmt |
| End Year Balance | $6,168,319 | EndYearBalanceAmt |
CY Minus3 Yr Endwmt Fund CYMinus3YrEndwmtFundGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Beginning Year Balance | $5,897,377 | BeginningYearBalanceAmt |
| Contributions | $200 | ContributionsAmt |
| Investment Earnings Or Losses | $546,324 | InvestmentEarningsOrLossesAmt |
| Grants Or Scholarships | -$237,896 | GrantsOrScholarshipsAmt |
| Administrative Expenses | -$13,198 | AdministrativeExpensesAmt |
| End Year Balance | $6,192,807 | EndYearBalanceAmt |
CY Minus4 Yr Endwmt Fund CYMinus4YrEndwmtFundGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Beginning Year Balance | $6,027,967 | BeginningYearBalanceAmt |
| Contributions | $5,200 | ContributionsAmt |
| Investment Earnings Or Losses | $119,369 | InvestmentEarningsOrLossesAmt |
| Grants Or Scholarships | -$240,000 | GrantsOrScholarshipsAmt |
| Administrative Expenses | -$15,159 | AdministrativeExpensesAmt |
| End Year Balance | $5,897,377 | EndYearBalanceAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Prmnnt Endowment Balance EOY | 0.38610 | PrmnntEndowmentBalanceEOYPct |
| Term Endowment Balance EOY | 0.61390 | TermEndowmentBalanceEOYPct |
| Endowments Held Unrelated Org | false | EndowmentsHeldUnrelatedOrgInd |
| Endowments Held Related Org | false | EndowmentsHeldRelatedOrgInd |
Leasehold Improvements LeaseholdImprovementsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Other Cost Or Other Basis | $1,141,552 | OtherCostOrOtherBasisAmt |
| Depreciation | $703,323 | DepreciationAmt |
| Book Value | $438,229 | BookValueAmt |
Equipment EquipmentGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Other Cost Or Other Basis | $17,376,846 | OtherCostOrOtherBasisAmt |
| Depreciation | $7,067,027 | DepreciationAmt |
| Book Value | $10,309,819 | BookValueAmt |
Other Land Buildings OtherLandBuildingsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Other Cost Or Other Basis | $51,570 | OtherCostOrOtherBasisAmt |
| Depreciation | $51,570 | DepreciationAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Book Value Land Buildings | $10,748,048 | TotalBookValueLandBuildingsAmt |
| Footnote Text | Yes (X) | FootnoteTextInd |
| Total Rev Etc Audited Fincl Stmt | $483,943,939 | TotalRevEtcAuditedFinclStmtAmt |
| Net Unrealized Gains Invst | -$7,965,542 | NetUnrealizedGainsInvstAmt |
| Donated Services And Use Fclts | $4,226,745 | DonatedServicesAndUseFcltsAmt |
| Other Revenue | $10,186,837 | OtherRevenueAmt |
| Revenue Not Reported | $6,448,040 | RevenueNotReportedAmt |
| Revenue Subtotal | $477,495,899 | RevenueSubtotalAmt |
| Investment Expenses Not Incld | $167,737 | InvestmentExpensesNotIncldAmt |
| Other Revenues Not Included | $80 | OtherRevenuesNotIncludedAmt |
| Revenue Not Reported Fincl Stmt | $167,817 | RevenueNotReportedFinclStmtAmt |
| Total Revenue Per Form990 | $477,663,716 | TotalRevenuePerForm990Amt |
| Tot Expns Etc Audited Fincl Stmt | $371,594,986 | TotExpnsEtcAuditedFinclStmtAmt |
| Donated Services Use Fclts | $4,226,745 | DonatedServicesUseFcltsAmt |
| Other Expenses Included | $8,173,806 | OtherExpensesIncludedAmt |
| Expenses Not Reported | $12,400,551 | ExpensesNotReportedAmt |
| Expenses Subtotal | $359,194,435 | ExpensesSubtotalAmt |
| Investment Expenses Not Incld2 | $653,744 | InvestmentExpensesNotIncld2Amt |
| Expenses Not Rpt Fincl Stmt | $653,744 | ExpensesNotRptFinclStmtAmt |
| Total Expenses Per Form990 | $359,848,179 | TotalExpensesPerForm990Amt |
Supplemental Information Detail SupplementalInformationDetail (6 entries)
| Form And Line ReferenceFormAndLineReferenceDesc | ExplanationExplanationTxt |
|---|---|
| SCHEDULE D, PAGE 2, PART III, LINE 4 | THE LLS COLLECTION IS OF PHOTOGRAPHS WHICH ARE USED FOR PUBLIC EXHIBITION AT FUNDRAISING EVENTS HELD TO SUPPORT LLS'S PROGRAMS. |
| SCHEDULE D, PAGE 2, PART V, LINE 4 | LLS'S ENDOWMENTS ARE INTENDED TO FUND RESEARCH AS WELL AS SUPPORT LLS'S PUBLIC EDUCATION PROGRAMS. |
| SCHEDULE D, PAGE 3, PART X | LLS, LLSRP, AND LLSRF QUALIFY AS CHARITABLE ORGANIZATIONS AS DEFINED BY INTERNAL REVENUE CODE SECTION 501(C)(3) AND, ACCORDINGLY, ARE EXEMPT FROM FEDERAL INCOME TAXES UNDER INTERNAL REVENUE CODE SECTION 501(A). ADDITIONALLY, SINCE THESE ORGANIZATIONS ARE PUBLICLY SUPPORTED, CONTRIBUTIONS QUALIFY FOR THE MAXIMUN CHARITABLE CONTRIBUTION DEDUCTION UNDER THE INTERNAL REVENUE CODE. LLSC IS REGISTERED AS A CHARITABLE ORGANIZATION UNDER THE INCOME TAX ACT (CANADA) AND IS, THEREFORE, NOT SUBJECT TO INCOME TAXES IF CERTAIN DISBURSEMENT REQUIREMENTS ARE MET. LLS AND ITS RELATED ENTITIES RECOGNIZE THE EFFECT OF TAX POSITIONS ONLY IF THOSE POSITIONS ARE MORE LIKELY THAN NOT TO BE SUSTAINED. INCOME GENERATED FROM ACTIVITIES UNRELATED TO LLS'S EXEMPT PURPOSE IS SUBJECT TO TAX UNDER INTERNAL REVENUE CODE SECTION 511. THERE WERE NOT ENTITIES THAT RECOGNIZED UNRELATED BUSINESS INCOME TAX LIABILITY FOR THE YEARS ENDED JUNE 30, 2021 AND JUNE 30, 2020. |
| SCHEDULE D, PAGE 4, PART XI, LINE 2D | LLS CANADA REVENUE 10,186,837 |
| SCHEDULE D, PAGE 4, PART XI, LINE 4B | MISC ROUNDING 80 |
| SCHEDULE D, PAGE 4, PART XII, LINE 2D | LLS CANADA EXPENSES 8,173,806 |
Schedule F IRS990ScheduleF
| Field | Value | IRS element (for citing) |
|---|---|---|
| Grant Records Maintained | Yes (true) | GrantRecordsMaintainedInd |
Account Activities Outside US AccountActivitiesOutsideUSGrp (5 entries)
| RegionRegionTxt | OfficesOfficesCnt | Type Of Activities ConductedTypeOfActivitiesConductedTxt | Specific Services ProvidedSpecificServicesProvidedTxt | Region Total ExpendituresRegionTotalExpendituresAmt |
|---|---|---|---|---|
| NORTH AMERICA | 4 | RESEARCH FUNDING | RESEARCH GRANTS | $357,600 |
| EUROPE | 8 | RESEARCH FUNDING | RESEARCH GRANTS | $9,662,921 |
| CENTRAL AMERICA & CARIBBEAN | 4 | INVESTMENTS | INVESTMENTS | $9,986,931 |
| MIDDLE EAST & NORTH AFRICA | 1 | RESEARCH FUNDING | RESEARCH GRANTS | $120,000 |
| EAST ASIA & THE PACIFIC | 6 | RESEARCH FUNDING | RESEARCH GRANTS | $1,764,767 |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Subtotal Offices | 23 | SubtotalOfficesCnt |
| Total Office | 23 | TotalOfficeCnt |
| Subtotal Spent | $21,892,219 | SubtotalSpentAmt |
| Total Spent | $21,892,219 | TotalSpentAmt |
Grants To Org Outside US GrantsToOrgOutsideUSGrp (17 entries)
| RegionRegionTxt | Purpose Of GrantPurposeOfGrantTxt | Cash GrantCashGrantAmt | Manner Of Cash DisbursementMannerOfCashDisbursementTxt | Valuation Method UsedValuationMethodUsedDesc |
|---|---|---|---|---|
| EUROPE | RESEARCH GRANT | $200,000 | WIRE | ACCRUAL |
| EUROPE | RESEARCH GRANT | $200,000 | WIRE | ACCRUAL |
| EAST ASIA AND PACIFIC | RESEARCH GRANT | $16,750 | WIRE | ACCRUAL |
| EUROPE | RESEARCH GRANT | $229,969 | WIRE | ACCRUAL |
| NORTH AMERICA | RESEARCH GRANT | $15,000 | WIRE | ACCRUAL |
| EUROPE | RESEARCH GRANT | $146,247 | WIRE | ACCRUAL |
| NORTH AMERICA | RESEARCH GRANT | $190,000 | WIRE | ACCRUAL |
| NORTH AMERICA | RESEARCH GRANT | $15,000 | WIRE | ACCRUAL |
| EAST ASIA AND PACIFIC | RESEARCH GRANT | $41,664 | WIRE | ACCRUAL |
| EAST ASIA AND PACIFIC | RESEARCH GRANT | $202,176 | WIRE | ACCRUAL |
| EAST ASIA AND PACIFIC | RESEARCH GRANT | $300,000 | WIRE | ACCRUAL |
| NORTH AMERICA | RESEARCH GRANT | $326,100 | WIRE | ACCRUAL |
| EUROPE | RESEARCH GRANT | $14,275 | WIRE | ACCRUAL |
| EAST ASIA AND PACIFIC | RESEARCH GRANT | $1,200,000 | WIRE | ACCRUAL |
| MIDDLE EAST | RESEARCH GRANT | $120,000 | WIRE | ACCRUAL |
| EUROPE | RESEARCH GRANT | $67,795 | WIRE | ACCRUAL |
| EUROPE | THERAPY ACCELERATION | $1,499,982 | WIRE | FMV |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Other Org | 17 | TotalOtherOrgCnt |
| Transfer To Foreign Corp | Yes (true) | TransferToForeignCorpInd |
| Interest In Foreign Trust | false | InterestInForeignTrustInd |
| Foreign Corp Ownership | Yes (true) | ForeignCorpOwnershipInd |
| Passive Foreign Investmest Co | Yes (true) | PassiveForeignInvestmestCoInd |
| Foreign Partnership | false | ForeignPartnershipInd |
| Boycott Countries | false | BoycottCountriesInd |
Supplemental Information Detail SupplementalInformationDetail (2 entries)
| Form And Line ReferenceFormAndLineReferenceDesc | ExplanationExplanationTxt |
|---|---|
| SCHEDULE F, PAGE 1, PART I, LINE 2 | FIDUCIARY RESPONSIBILITY AND TRANSPARENCY TO OUR DONORS IS A HIGH PRIORITY. THE LEUKEMIA & LYMPHOMA SOCIETY (LLS) PLACES CONSIDERABLE EMPHASIS ON THE OVERSIGHT OF GRANT SPENDING. TO ACCOMPLISH THIS WE REQUIRE THE SUBMISSION OF ANNUAL FINANCIAL REPORTS FOR EACH OF OUR ACTIVE GRANTS. THE REPORT MUST BE SIGNED BY THE FINANCIAL OFFICER AND/OR THE DESIGNATED OFFICIAL OF THE INSTITUTION HOSTING THE AWARD. AT THE END OF THE GRANT, WE REQUIRE A FINAL FINANCIAL REPORT THAT PROVIDES AN OVERVIEW OF ALL SPENDING THROUGH THE DURATION OF THE AWARD. WE REQUIRE SPECIFIC ACCOUNTING OF SPENDING ON PERSONNEL, CONSULTANTS, EQUIPMENT PURCHASES, SUPPLIES, TRAVEL, PATIENT CARE COSTS, ANIMAL CARE COSTS, AND ANY OTHER EXPENSE A GRANTEE MAY INCUR. WE HAVE SPECIFIC INSTRUCTIONS AND DOLLAR AMOUNT LIMITATIONS SET FOR MANY OF THESE CATEGORIES DEPENDING ON THE AWARD TYPE. FINANCIAL REPORTS ARE REVIEWED FOR NUMERICAL ACCURACY, ADHERENCE TO OUR GUIDELINES, AND FOR THE VERIFICATION OF APPROVAL FROM THE INSTITUTION'S FINANCIAL OFFICER. IF THE GRANTEE DOES NOT SUBMIT AN ANNUAL FINANCIAL REPORT BY THE DUE DATE OUTLINED IN THEIR CONTRACT, FUNDING IS SUSPENDED UNTIL LLS RECEIVES AND APPROVES THE DELINQUENT REPORT. THE ACCOUNTING METHOD UTILIZED FOR GRANTS REPORTED ON PART II IS THE ACCRUAL METHOD AS CONSISTENT WITH BOOKS AND RECORDS. |
| SCHEDULE F, PAGE 1, PART I, LINE 3 | NORTH AMERICA 357,600 0 EUROPE 9,662,921 0 CENTRAL AMERICA & CARIBBEAN 0 9,986,931 MIDDLE EAST & NORTH AFRICA 120,000 0 EAST ASIA & THE PACIFIC 1,764,767 0 |
Schedule G IRS990ScheduleG
| Field | Value | IRS element (for citing) |
|---|---|---|
| Mail Solicitations | Yes (X) | MailSolicitationsInd |
| Email Solicitations | Yes (X) | EmailSolicitationsInd |
| Phone Solicitations | Yes (X) | PhoneSolicitationsInd |
| In Person Solicitations | Yes (X) | InPersonSolicitationsInd |
| Solicitation Of Non Govt Grants | Yes (X) | SolicitationOfNonGovtGrantsInd |
| Special Fundraising Events | Yes (X) | SpecialFundraisingEventsInd |
| Agrmt Prof Fundraising Acty | Yes (true) | AgrmtProfFundraisingActyInd |
Fundraiser Activity Info FundraiserActivityInfoGrp (4 entries)
| Address Line1USAddress/AddressLine1Txt | CityUSAddress/CityNm | State AbbreviationUSAddress/StateAbbreviationCd | ZIPUSAddress/ZIPCd | ActivityActivityTxt | Fundraiser Control Of FundsFundraiserControlOfFundsInd | Retained By ContractorRetainedByContractorAmt | Net To OrganizationNetToOrganizationAmt | Gross ReceiptsGrossReceiptsAmt |
|---|---|---|---|---|---|---|---|---|
| RESOURCE ONE | ||||||||
| 2900 EAST APACHE STREET | TULSO | OK | 74110 | DIRECT MAI | false | $4,630,228 | -$4,630,228 | |
| THOMPSON HABIB & DENISON | ||||||||
| 80 HAYDEN AVENUE SUITE 300 | LEXINGTON | MA | 02421 | DIRECT MAI | false | $687,311 | -$687,311 | |
| MAIL AMERICA COMMUNICATIONS INC | ||||||||
| PO BOX 870 | FORREST | VA | 245510870 | DIRECT MAI | false | $190,269 | -$190,269 | |
| COINSTAR | ||||||||
| 1800 114TH AVENUE SE | BELLEVUE | WA | 98004 | COIN COLLE | false | $15,797 | $381,989 | $397,786 |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Gross Receipts | $397,786 | TotalGrossReceiptsAmt |
| Total Retained By Contractors | $5,523,605 | TotalRetainedByContractorsAmt |
| Total Net To Organization | -$5,125,819 | TotalNetToOrganizationAmt |
| All States | All States | AllStatesCd |
Fundraising Event Information FundraisingEventInformationGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Event1 | MAN/WOMAN OF TH | Event1Nm |
| Gross Receipts Event1 | $4,219,087 | GrossReceiptsEvent1Amt |
| Charitable Contri Event1 | $4,209,899 | CharitableContriEvent1Amt |
| Gross Revenue Event1 | $9,188 | GrossRevenueEvent1Amt |
| Non Cash Prizes Event1 | $7,675 | NonCashPrizesEvent1Amt |
| Rent Facility Costs Event1 | $830 | RentFacilityCostsEvent1Amt |
| Food And Beverage Event1 | $683 | FoodAndBeverageEvent1Amt |
| Other Direct Expenses Event1 | $3,252 | OtherDirectExpensesEvent1Amt |
| Event2 | STUDENT OF THE | Event2Nm |
| Gross Receipts Event2 | $3,335,276 | GrossReceiptsEvent2Amt |
| Charitable Contri Event2 | $3,324,868 | CharitableContriEvent2Amt |
| Gross Revenue Event2 | $10,408 | GrossRevenueEvent2Amt |
| Non Cash Prizes Event2 | $10,302 | NonCashPrizesEvent2Amt |
| Food And Beverage Event2 | $106 | FoodAndBeverageEvent2Amt |
| Other Direct Expenses Event2 | $3,732 | OtherDirectExpensesEvent2Amt |
| Other Events Total | 339 | OtherEventsTotalCnt |
| Gross Receipts Other Events | $157,393,006 | GrossReceiptsOtherEventsAmt |
| Charitable Contri Other Events | $152,592,466 | CharitableContriOtherEventsAmt |
| Gross Revenue Other Events | $4,800,540 | GrossRevenueOtherEventsAmt |
| Non Cash Prizes Other Events | $3,364,586 | NonCashPrizesOtherEventsAmt |
| Rent Fclty Costs Other Events | $931,964 | RentFcltyCostsOtherEventsAmt |
| Food And Beverage Other Events | $162,918 | FoodAndBeverageOtherEventsAmt |
| Entertainment Other Events | $270,606 | EntertainmentOtherEventsAmt |
| Oth Direct Expnss Other Events | $916,475 | OthDirectExpnssOtherEventsAmt |
| Gross Receipts Total | $164,947,369 | GrossReceiptsTotalAmt |
| Charitable Contributions Tot | $160,127,233 | CharitableContributionsTotAmt |
| Gross Revenue Total Events | $4,820,136 | GrossRevenueTotalEventsAmt |
| Non Cash Prizes Total Events | $3,382,563 | NonCashPrizesTotalEventsAmt |
| Rent Fclty Costs Total Events | $932,794 | RentFcltyCostsTotalEventsAmt |
| Food And Beverage Total Events | $163,707 | FoodAndBeverageTotalEventsAmt |
| Entertainment Total Events | $270,606 | EntertainmentTotalEventsAmt |
| Oth Direct Expnss Total Events | $923,459 | OthDirectExpnssTotalEventsAmt |
| Direct Expense Summary Events | $5,673,129 | DirectExpenseSummaryEventsAmt |
| Net Income Summary | -$852,993 | NetIncomeSummaryAmt |
Gaming Information GamingInformationGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Volunteer Labor Bingo | false | VolunteerLaborBingoInd |
| Volunteer Labor Pull Tabs | false | VolunteerLaborPullTabsInd |
| Gross Revenue Other Gaming | $77,510 | GrossRevenueOtherGamingAmt |
| Non Cash Prizes Other Gaming | $2,200 | NonCashPrizesOtherGamingAmt |
| Volunteer Labor Other Gaming | false | VolunteerLaborOtherGamingInd |
| Gross Revenue Total Gaming | $77,510 | GrossRevenueTotalGamingAmt |
| Non Cash Prizes Total Gaming | $2,200 | NonCashPrizesTotalGamingAmt |
| Direct Expense Summary Gaming | $2,200 | DirectExpenseSummaryGamingAmt |
| Net Gaming Income Summary | $75,310 | NetGamingIncomeSummaryAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| States Where Gaming Conducted | OH | StatesWhereGamingConductedCd |
| States Where Gaming Conducted | FL | StatesWhereGamingConductedCd |
| Licensed | Yes (true) | LicensedInd |
| License Suspended Etc | false | LicenseSuspendedEtcInd |
| Gaming With Nonmembers | false | GamingWithNonmembersInd |
| Member Of Other Entity | false | MemberOfOtherEntityInd |
| Gaming Own Facility | 1.00000 | GamingOwnFacilityPct |
| Individual With Books | GORDON MILLER JR | IndividualWithBooksNm |
Persons With Books US Address PersonsWithBooksUSAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 3 INTERNATIONAL DRIVE SUITE 200 | AddressLine1Txt |
| City | RYE BROOK | CityNm |
| State Abbreviation | NY | StateAbbreviationCd |
| ZIP | 10573 | ZIPCd |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Cntrct With3rd Prty For Game Rev | false | CntrctWith3rdPrtyForGameRevInd |
| Gaming Manager Person | SEE SCHEDULE G PART IV | GamingManagerPersonNm |
| Charitable Distribution Rqr | false | CharitableDistributionRqrInd |
Supplemental Information Detail SupplementalInformationDetail
| Field | Value | IRS element (for citing) |
|---|---|---|
| Form And Line Reference | SCHEDULE G, PART IV | FormAndLineReferenceDesc |
| Explanation | SCHEDULE G PART I, LINE 2B LLS USED RESOURCE ONE, THOMPSON, HABIB & DENISON, AND MAIL AMERICA COMMUNICATIONS FOR ITS NATIONAL COMMUNITY CAMPAIGN AND DIRECT MAIL PROGRAMS. LLS USED COINSTAR FOR ITS COIN COLLECTION. SCHEDULE G PART II - LINE 2 CONTRIBUTIONS REPRESENT THE CASH DONATIONS IN EXCESS OF FAIR MARKET VALUE BENEFITS PROVIDED TO THE DONOR. SCHEDULE G PART III - LINE 9 - STATES WITH GAMING OPERATIONS UTAH, OHIO SCHEDULE G PART III - LINE 16 THE LEUKEMIA & LYMPHOMA SOCIETY DOES NOT HAVE AN OVERALL MANAGER FOR GAMING ACTIVITIES. EACH GAMING EVENT IS MANAGED LOCALLY BY THE SPECIFIC REGIONAL STAFF. | ExplanationTxt |
Schedule I IRS990ScheduleI
| Field | Value | IRS element (for citing) |
|---|---|---|
| Grant Records Maintained | Yes (true) | GrantRecordsMaintainedInd |
Recipient Table RecipientTable (72 entries)
| Address Line1USAddress/AddressLine1Txt | Address Line2USAddress/AddressLine2Txt | CityUSAddress/CityNm | State AbbreviationUSAddress/StateAbbreviationCd | ZIPUSAddress/ZIPCd | Recipient EINRecipientEIN | IRC SectionIRCSectionDesc | Cash GrantCashGrantAmt | Valuation Method UsedValuationMethodUsedDesc | Purpose Of GrantPurposeOfGrantTxt |
|---|---|---|---|---|---|---|---|---|---|
| ALBERT EINSTEIN COLLEGE OF MEDICINE | |||||||||
| RESEARCH FINANCE | 1300 MORRIS PARK AVE BELFER 1108 | BRONX | NY | 10461 | 472209056 | 3 | $602,666 | ACCRUAL | RESEARCH GRANT |
| ATRIUM HEALTH FOUNDATION | |||||||||
| 208 EAST BOULEVARD | ATTN ELECTA MCPHERSON | CHARLOTTE | NC | 28203 | 566060481 | 3 | $110,000 | ACCRUAL | RESEARCH GRANT |
| BAYLOR COLLEGE OF MEDICINE | |||||||||
| BAYLOR COLLEGE OF MEDICINE | P O BOX 301207 | DALLAS | TX | 753031207 | 741613878 | 3 | $1,275,623 | ACCRUAL | RESEARCH GRANT |
| BE THE MATCH FOUNDATION | |||||||||
| 500 N 5TH STREET | MINNEAPOLIS | MN | 55401 | 411704340 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT | |
| BECKMAN RESEARCH INSTITUTE OF THE C | |||||||||
| 1500 EAST DUARTE ROAD | ATTN VALERIE BINGHAM | DUARTE | CA | 91010 | 953432210 | 3 | $1,331,722 | ACCRUAL | RESEARCH GRANT |
| BOARD OF TRUSTEES OF THE LELAND STA | |||||||||
| STANFORD UNIVERSITY LOCKBOX | PO BOX 44253 | SAN FRANCISCO | CA | 941444253 | 941156365 | 3 | $1,852,192 | ACCRUAL | RESEARCH GRANT |
| BOSTON CHILDREN'S HOSPITAL | |||||||||
| ATTN RESEARCH FINANCE | PO BOX 414413 | BOSTON | MA | 022414413 | 042774441 | 3 | $11,299 | ACCRUAL | RESEARCH GRANT |
| BOSTON UNIVERSITY RESEARCH ACCOUNTI | |||||||||
| PO BOX 28763 | NEW YORK | NY | 100878763 | 042103547 | 3 | $139,381 | ACCRUAL | RESEARCH GRANT | |
| BRIGHAM AND WOMENS HOSPITAL | |||||||||
| RESEARCH | PO BOX 3149 | BOSTON | MA | 022413149 | 042312909 | 3 | $104,500 | ACCRUAL | RESEARCH GRANT |
| BROAD INSTITUTE INC | |||||||||
| 7 CAMBRIDGE CENTER | CAMBRIDGE | MA | 02142 | 263428781 | 3 | $15,000 | ACCRUAL | RESEARCH GRANT | |
| CINCINNATI CHILDREN'S HOSPITAL MEDI | |||||||||
| 3333 BURNET AVENUE ML 4900 | CINCINATTI | OH | 45229 | 310833936 | 3 | $253,350 | ACCRUAL | RESEARCH GRANT | |
| CLEVELAND CLINIC FOUNDATION | |||||||||
| 9500 EUCLID AVENUE | CLEVELAND | OH | 44195 | 340714585 | 3 | $190,000 | ACCRUAL | RESEARCH GRANT | |
| DANA-FARBER CANCER INSTITUTE | |||||||||
| RESEARCH ACCOUNTING MAIL STOP BP43 | 450 BROOKLINE AVENUE | BOSTON | MA | 02215 | 042263040 | 3 | $3,256,293 | ACCRUAL | RESEARCH GRANT |
| EMORY UNIVERSITY | |||||||||
| EMORY UNIVERSITY | PO BOX 935084 | ATLANTA | GA | 311935084 | 582137993 | 3 | $550,000 | ACCRUAL | RESEARCH GRANT |
| FRED HUTCHINSON CANCER RESEARCH CEN | |||||||||
| 1100 FAIRVIEW AVENUE NORTH J6-300 | SEATTLE | WA | 981091024 | 237156071 | 3 | $2,021,795 | ACCRUAL | RESEARCH GRANT | |
| H LEE MOFFITT CANCER CENTER & RESE | |||||||||
| PO BOX 742801 | ATLANTA | GA | 303742801 | 593238634 | 3 | $61,919 | ACCRUAL | RESEARCH GRANT | |
| HACKENSACK MERIDIAN HEALTH | |||||||||
| 40 PROSPECT AVENUE | ATTN DAVID CANDELMO OFFICE OF RE | HACKENSACK | NJ | 07601 | 221487576 | 3 | $104,194 | ACCRUAL | RESEARCH GRANT |
| HARVARD MEDICAL SCHOOL | |||||||||
| PO BOX 415649 | BOSTON | MA | 022415649 | 042103580 | 3 | $56,833 | ACCRUAL | RESEARCH GRANT | |
| ICAHN SCHOOL OF MEDICINE AT MOUNT S | |||||||||
| ATTN RAJ APPAVU | ONE GUSTAVE L LEVY PLACE BOX 350 | NEW YORK | NY | 10029 | 136171197 | 3 | $120,000 | ACCRUAL | RESEARCH GRANT |
| INDIANA UNIVERSITY | |||||||||
| OFFICE OF RESEARCH ADMINISTRATION | PO BOX 78000 | DETROIT | MI | 482780867 | 356018940 | 3 | $347,105 | ACCRUAL | RESEARCH GRANT |
| INTERNATIONAL WALDENSTROM'S MACROGL | |||||||||
| 6144 CLARK CENTER AVE | SARASOTA | FL | 34238 | 541784426 | 3 | $50,000 | ACCRUAL | RESEARCH GRANT | |
| JOAN & SANFORD I WEILL MEDICAL COL | |||||||||
| 575 LEXINGTON AVE 9TH FL | ATTN MELISSA PARAY | NEW YORK | NY | 10022 | 131623978 | 3 | $645,500 | ACCRUAL | RESEARCH GRANT |
| MASSACHUSETTS GENERAL HOSPITAL | |||||||||
| MGH RESEARCH FINANCE | PO BOX 414876 | BOSTON | MA | 022414876 | 041564655 | 3 | $1,118,749 | ACCRUAL | RESEARCH GRANT |
| MASSACHUSETTS INSTITUTE OF TECHNOLO | |||||||||
| 77 MASSACHUSETTS AVE | NE18-901 | CAMBRIDGE | MA | 02139 | 042103594 | 3 | $57,000 | ACCRUAL | RESEARCH GRANT |
| MAYO CLINIC ROCHESTER | |||||||||
| MAYO CLINIC RESEARCH | PO BOX 860334 | MINNEAPOLIS | MN | 554860334 | 416011702 | 3 | $260,000 | ACCRUAL | RESEARCH GRANT |
| MYELOPROLIFERATIVE NEOPLASMS RESEAR | |||||||||
| 180 N MICHIGAN AVENUE | SUITE 1870 | CHICAGO | IL | 60601 | 364330967 | 3 | $50,000 | ACCRUAL | RESEARCH GRANT |
| NEW YORK UNIVERSITY SCHOOL OF MEDIC | |||||||||
| SPONSORED PROGRAMS | PO BOX 415026 | BOSTON | MA | 022414150 | 135562308 | 3 | $858,243 | ACCRUAL | RESEARCH GRANT |
| NORTHWESTERN UNIVERSITY | |||||||||
| ACCOUNTING SERVICES FOR RESEARCH | 633 CLARK - ROOM G547 | EVANSTON | IL | 60208 | 362167817 | 3 | $414,500 | ACCRUAL | RESEARCH GRANT |
| OSU FOUNDATION | |||||||||
| 1960 KENNY ROAD 4TH FLOOR | COLUMBUS | OH | 432101016 | 316025986 | 3 | $612,312 | ACCRUAL | RESEARCH GRANT | |
| PERELMAN SCHOOL OF MEDICINE AT THE | |||||||||
| OFFICE OF RESEARCH SERVICES | 3451 WALNUT STREET FRANKLIN BLDG P- | PHILADELPHIA | PA | 191046205 | 231352685 | 3 | $121,898 | ACCRUAL | RESEARCH GRANT |
| REGENTS OF THE UNIVERSITY OF MICHIG | |||||||||
| BOX 223131 | PITTSBURGH | PA | 152512131 | 386006309 | 3 | $582,818 | ACCRUAL | RESEARCH GRANT | |
| ROCKEFELLER UNIVERSITY | |||||||||
| 1230 YORK AVENUE BOX 82 | NEW YORK | NY | 10021 | 131624158 | 3 | $190,000 | ACCRUAL | RESEARCH GRANT | |
| SEATTLE CHILDREN'S HOSPITAL | |||||||||
| 4800 SAND POINT WAY NE | SEATTLE | WA | 98105 | 911156519 | 3 | $125,000 | ACCRUAL | RESEARCH GRANT | |
| SLOAN KETTERING INSTITUTE FOR CANCE | |||||||||
| SLOAN KETTERING INSTITUTE FOR CANCE | MSKC FINANCE GENERAL POST OFFICE PO | NEW YORK | NY | 10087 | 131924236 | 3 | $484,600 | ACCRUAL | RESEARCH GRANT |
| ST JUDE CHILDREN'S RESEARCH HOSPIT | |||||||||
| PO BOX 1000 DEPT 949 | MEMPHIS | TN | 381480949 | 620646012 | 3 | $489,500 | ACCRUAL | RESEARCH GRANT | |
| TEMPLE UNIVERSITY | |||||||||
| RESEARCH ACCOUNTING SERVICES | PO BOX 824242 | PHILADELPHIA | PA | 191824242 | 231365971 | 3 | $210,000 | ACCRUAL | RESEARCH GRANT |
| THE CHILDREN'S HOSPITAL OF PHILADEL | |||||||||
| LOCKBOX 1457 | PO BOX 8500 | PHILADELPHIA | PA | 191781457 | 231352166 | 3 | $8,325 | ACCRUAL | RESEARCH GRANT |
| THE JACKSON LABORATORY | |||||||||
| 600 MAIN STREET | BAR HARBOR | ME | 046091523 | 010211513 | 3 | $90,000 | ACCRUAL | RESEARCH GRANT | |
| THE JOHNS HOPKINS UNIVERSITY SCHOOL | |||||||||
| JOHNS HOPKINS UNIVERSITY CENTRAL LO | 12529 COLLECTIONS CENTER DRIVE | CHICAGO | IL | 60693 | 520595110 | 3 | $290,000 | ACCRUAL | RESEARCH GRANT |
| THE OHIO STATE UNIVERSITY | |||||||||
| 1960 KENNY ROAD 4TH FLOOR | ATTN RICHARD BRADBURY | COLUMBUS | OH | 432101016 | 316025986 | 3 | $162,517 | ACCRUAL | RESEARCH GRANT |
| THE REGENTS OF THE UNIVERSITY OF CA | |||||||||
| 9500 GILMAN DRIVE MC 0009 | LA JOLLA | CA | 920930009 | 956006144 | 3 | $500,000 | ACCRUAL | RESEARCH GRANT | |
| THE REGENTS OF THE UNIVERSITY OF CA | |||||||||
| UCSF MAIN DEPOSITORY | PO BOX 748872 | LOS ANGELES | CA | 900744872 | 946036493 | 3 | $363,479 | ACCRUAL | RESEARCH GRANT |
| THE TRUSTEES OF COLUMBIA UNIVERSITY | |||||||||
| SPONSORED PROJECTS FINANCE | PO BOX 29789 | NEW YORK | NY | 100879789 | 135598093 | 3 | $10,000 | ACCRUAL | RESEARCH GRANT |
| THE TRUSTEES OF COLUMBIA UNIVERSITY | |||||||||
| SPONSORED PROJECTS FINANCE | PO BOX 29789 | NEW YORK | NY | 100879789 | 135598093 | 3 | $172,689 | ACCRUAL | RESEARCH GRANT |
| THE TRUSTEES OF THE UNIVERSITY OF P | |||||||||
| OFFICE OF RESEARCH SERVICES | 3451 WALNUT STREET FRANKLIN BLDG P | PHILADELPHIA | PA | 191046205 | 231352685 | 3 | $1,424,086 | ACCRUAL | RESEARCH GRANT |
| THE UNIVERSITY OF ALABAMA AT BIRMIN | |||||||||
| 1530 3RD AVENUE SOUTH SUITE 1170 | BIRMINGHAM | AL | 352940111 | 636005396 | 3 | $68,350 | ACCRUAL | RESEARCH GRANT | |
| THE UNIVERSITY OF CHICAGO | |||||||||
| 5841 S MARYLAND AVE MC6092 | CHICAGO | IL | 60637 | 362177139 | 3 | $100,000 | ACCRUAL | RESEARCH GRANT | |
| THE UNIVERSITY OF NORTH CAROLINA AT | |||||||||
| OFFICE OF SPONSORED RESEARCH IN CA | PO BOX 402420 | ATLANTA | GA | 303842420 | 566001393 | 3 | $304,435 | ACCRUAL | RESEARCH GRANT |
| THE UNIVERSITY OF TEXAS MD ANDERSON | |||||||||
| ATTN GRANTS AND CONTRACTS | PO BOX 4266 | HOUSTON | TX | 772104266 | 746001118 | 3 | $1,631,191 | ACCRUAL | RESEARCH GRANT |
| THE UNIVERSITY OF TEXAS SOUTHWESTER | |||||||||
| PO BOX 841753 | DALLAS | TX | 752841753 | 756002868 | 3 | $304,500 | ACCRUAL | RESEARCH GRANT | |
| THE UNIVERSITY OF UTAH | |||||||||
| 201 S PRESIDENTS CIRCLE RM 145 | ACCOUNTS PAYABLE | SALT LAKE CITY | UT | 841129003 | 876000525 | 3 | $104,500 | ACCRUAL | RESEARCH GRANT |
| TUFTS MEDICAL CENTER | |||||||||
| 800 WASHINGTON STREET 453 | BOSTON | MA | 02111 | 042103634 | 3 | $375,680 | ACCRUAL | RESEARCH GRANT | |
| UNIVERSITY OF CALIFORNIA IRVINE | |||||||||
| OFFICE OF RESEARCH ADMINISTRATION | 300 UNIVERSITY TOWER UNIVERSITY OF | IRVINE | CA | 926977600 | 952540117 | 3 | $190,000 | ACCRUAL | RESEARCH GRANT |
| UNIVERSITY OF CHICAGO | |||||||||
| 6054 SOUTH DREXEL AVE | SUITE 300 | CHICAGO | IL | 60637 | 362177139 | 3 | $287,302 | ACCRUAL | RESEARCH GRANT |
| UNIVERSITY OF COLORADO DENVER ANSC | |||||||||
| ANSCHUTZ MEDICAL CAMPUS BLDG 500 | PO BOX 6508 | AURORA | CO | 80045 | 846000555 | 3 | $678,754 | ACCRUAL | RESEARCH GRANT |
| UNIVERSITY OF COLORADO-DENVER | |||||||||
| 12700 E 19TH AVENUE | AURORA | CO | 80045 | 846000555 | 3 | $200,000 | ACCRUAL | RESEARCH GRANT | |
| UNIVERSITY OF FLORIDA | |||||||||
| 33 TIGERT HALL | P O BOX 113001 | GAINESVILLE | FL | 326113001 | 596002052 | 3 | $1,743,668 | ACCRUAL | RESEARCH GRANT |
| UNIVERSITY OF KENTUCKY | |||||||||
| 500 SOUTH LIMESTONE | 109 KINKEAD HALL | LEXINGTON | KY | 405060001 | 616033693 | 3 | $56,997 | ACCRUAL | RESEARCH GRANT |
| UNIVERSITY OF MARYLAND BALTIMORE | |||||||||
| PO BOX 41428 | BALTIMORE | MD | 212036428 | 526002033 | 3 | $50,000 | ACCRUAL | RESEARCH GRANT | |
| UNIVERSITY OF MIAMI | |||||||||
| OFFICE OF RESEARCH ADMINISTRATION | PO BOX 405803 | ATLANTA | GA | 303845803 | 590624458 | 3 | $1,161,500 | ACCRUAL | RESEARCH GRANT |
| UNIVERSITY OF NOTRE DAME | |||||||||
| 511 MAIN BUILDING | NOTRE DAME | IN | 46556 | 350868188 | 3 | $190,000 | ACCRUAL | RESEARCH GRANT | |
| UNIVERSITY OF SOUTHERN CALIFORNIA | |||||||||
| SPONSORED PROJECTS ACCOUNTING | FILE NO 52095 | LOS ANGELES | CA | 90089 | 951642394 | 3 | $55,000 | ACCRUAL | RESEARCH GRANT |
| UNIVERSITY OF VIRGINIA | |||||||||
| ATTN OFFICE OF SPONSORED PROGRAMS | PO BOX 400195 | CHARLOTTESVILLE | VA | 229044195 | 237173411 | 3 | $104,194 | ACCRUAL | RESEARCH GRANT |
| VAN ANDEL RESEARCH INSTITUTE | |||||||||
| 333 BOSTWICK AVE NE | GRAND RAPIDS | MI | 49503 | 522000820 | 3 | $5,500 | ACCRUAL | RESEARCH GRANT | |
| VANDERBILT UNIVERSITY MEDICAL CENTE | |||||||||
| DEPT OF FINANCE ATTN STEVE TODD | DEPT 1236 PO BOX 121236 | DALLAS | TX | 75312 | 620476822 | 3 | $243,750 | ACCRUAL | RESEARCH GRANT |
| WASHINGTON UNIVERSITY IN ST LOUIS | |||||||||
| CAMPUS BOX 1034 | 700 ROSEDALE AVENUE | ST LOUIS | MO | 63130 | 430653611 | 3 | $220,000 | ACCRUAL | RESEARCH GRANT |
| WASHINGTON UNIVERSITY SCHOOL OF MED | |||||||||
| SPONSORED PROJECTS ACCOUNTING | 700 ROSEDALE AVENUE CAMPUS BOX 1034 | ST LOUIS | MO | 631121408 | 430653611 | 3 | $455,000 | ACCRUAL | RESEARCH GRANT |
| WESTERN INSTITUTE FOR VETERANS RESE | |||||||||
| PO BOX 58719 | SALT LAKE CITY | UT | 84158 | 870470748 | 3 | $70,882 | ACCRUAL | RESEARCH GRANT | |
| YALE UNIVERSITY | |||||||||
| OFFICE OF SPONSORED PROJECTS | PO BOX 1873 | NEW HAVEN | CT | 065201873 | 060646973 | 3 | $312,500 | ACCRUAL | RESEARCH GRANT |
| CONSTELLATION | |||||||||
| 215 FIRST STREET | SUITE 200 | CAMBRIDGE | MA | 02142 | 270031381 | $50,000 | FMV | THERAPY ACCELERATION | |
| ABINTUS BIO INC | |||||||||
| 10355 SCIENCE CENTER DR | 250 | SAN DIEGO | CA | 92121 | 844349617 | $250,000 | FMV | THERAPY ACCELERATION | |
| JOHNS HOPKINS UNIV | |||||||||
| 733 N BROADWAY | BALTIMORE | MD | 21231 | 520595110 | $20,000 | FMV | THERAPY ACCELERATION | ||
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total501c3 Org | 75 | Total501c3OrgCnt |
Grants Other Asst To Indiv In US GrantsOtherAsstToIndivInUSGrp (11 entries)
| Grant TypeGrantTypeTxt | RecipientRecipientCnt | Cash GrantCashGrantAmt |
|---|---|---|
| COPAY ASSISTANCE CLL | 3388 | $13,280,647 |
| COPAY ASSISTANCE LYMPHOMA | 3480 | $10,533,758 |
| COPAY ASSISTANCE MDS | 2987 | $9,998,616 |
| COPAY ASSISTANCE MYELOMA | 11872 | $61,505,457 |
| COPAY ASSISTANCE MANTEL | 894 | $2,975,201 |
| COPAY ASSISTANCE WALDENST | 567 | $2,168,330 |
| COPAY ASSISTANCE ALL | 64 | $238,812 |
| COPAY ASSISTANCE AML | 3288 | $10,693,411 |
| COPAY ASSISTANCE CML | 152 | $237,174 |
| PATIENT TRAVEL ASSISTANC | 4944 | $2,903,009 |
| PATIENT AID | 9863 | $4,091,519 |
Supplemental Information Detail SupplementalInformationDetail
| Field | Value | IRS element (for citing) |
|---|---|---|
| Form And Line Reference | SCHEDULE I, PAGE 1, PART I, LINE 2 | FormAndLineReferenceDesc |
| Explanation | FIDUCIARY RESPONSIBILITY AND TRANSPARENCY TO OUR DONORS IS A HIGH PRIORITY. THE LEUKEMIA & LYMPHOMA SOCIETY (LLS) PLACES CONSIDERABLE EMPHASIS ON THE OVERSIGHT OF GRANT SPENDING. TO ACCOMPLISH THIS WE REQUIRE THE SUBMISSION OF ANNUAL FINANCIAL REPORTS FOR EACH OF OUR ACTIVE GRANTS. THE REPORT MUST BE SIGNED BY THE FINANCIAL OFFICER AND/OR THE DESIGNATED OFFICIAL OF THE INSTITUTION HOSTING THE AWARD. AT THE END OF THE GRANT, WE REQUIRE A FINAL FINANCIAL REPORT THAT PROVIDES AN OVERVIEW OF ALL SPENDING THROUGH THE DURATION OF THE AWARD. WE REQUIRE SPECIFIC ACCOUNTING OF SPENDING ON PERSONNEL, CONSULTANTS, EQUIPMENT PURCHASES, SUPPLIES, TRAVEL, PATIENT CARE COSTS, ANIMAL CARE COSTS, AND ANY OTHER EXPENSE A GRANTEE MAY INCUR. WE HAVE SPECIFIC INSTRUCTIONS AND DOLLAR AMOUNT LIMITATIONS SET FOR MANY OF THESE CATEGORIES DEPENDING ON THE AWARD TYPE. FINANCIAL REPORTS ARE REVIEWED FOR NUMERICAL ACCURACY, ADHERENCE TO OUR GUIDELINES, AND FOR THE VERIFICATION OF APPROVAL FROM THE INSTITUTION'S FINANCIAL OFFICER. IF THE GRANTEE DOES NOT SUBMIT AN ANNUAL FINANCIAL REPORT BY THE DUE DATE OUTLINED IN THEIR CONTRACT, FUNDING IS SUSPENDED UNTIL LLS RECEIVES AND APPROVES THE DELINQUENT REPORT. PATIENT FINANCIAL AID: THE LEUKEMIA AND LYMPHOMA SOCIETY (LLS) REGULARLY RECEIVES CALLS FROM PATIENTS WHO CANNOT MOVE FORWARD WITH THEIR POTENTIALLY LIFE-SAVING TREATMENTS BECAUSE THEY CANNOT AFFORD TO PAY FOR MANY EXPENSES RELATED TO THEIR TREATMENT. SOMETIMES PATIENTS HAVE TO CHOOSE BETWEEN BASIC NEEDS SUCH AS FOOD OR SHELTER AND THEIR HEALTH CARE TREATMENT EXPENSES. IN AN EFFORT TO ALLEVIATE SUCH HARDSHIPS, LLS HAS ESTABLISHED A PATIENT FINANCIAL AID PROGRAM THAT PROVIDES APPLICANTS, WHO RESIDE IN THE US AND HAVE A BLOOD CANCER DIAGNOSIS, A ONE-TIME ANNUAL STIPEND TO HELP DEFER SOME OF THESE EXPENSES. LLS ROUTINELY CONDUCTS AN OPERATIONAL AUDIT VERIFYING APPLICANTS ARE IN COMPLIANCE WITH PROGRAM GUIDELINES AND PROGRAM CRITERIA. CO-PAY ASSISTANCE: PATIENT APPLICATIONS ARE PROCESSED ON A FIRST COME, FIRST SERVED BASIS. ELIGIBLE PATIENTS MUST RESIDE IN THE UNITED STATES OR PUERTO RICO, HAVE A PROGRAM COVERED BLOOD CANCER DIAGNOSIS CONFIRMED BY A PHYSICIAN, MAINTAIN MEDICAL/PRESCRIPTION INSURANCE AND HAVE HOUSEHOLD INCOME AT OR BELOW 500% OF THE US FEDERAL POVERTY LEVEL AS ADJUSTED BY HOUSEHOLD SIZE AND COST OF LIVING INDEX. PATIENTS MUST PROVIDE PROOF OF INSURANCE AND INCOME. QUALIFYING PATIENTS ARE APPROVED FOR A TWELVE MONTH COVERAGE PERIOD. PATIENT TRAVEL ASSISTANCE: THE LEUKEMIA AND LYMPHOMA SOCIETY (LLS) REGULARLY RECEIVES CALLS FROM PATIENTS WHO CANNOT MOVE FORWARD WITH THEIR POTENTIALLY LIFE-SAVING TREATMENTS BECAUSE THEY CANNOT AFFORD TO PAY FOR TRANSPORTATION TO GET TO THEIR PROVIDERS, E.G. DOCTORS, HOSPITALS, TRANSPLANT CENTERS, AND RESEARCH OR CLINICAL TRIAL CENTERS. SOMETIMES PATIENTS HAVE TO TRAVEL OUT-OF-STATE TO GET THEIR PRESCRIBED AND RECOMMENDED TREATMENTS, OFTENTIMES RESULTING IN PATIENTS HAVING TO CHOOSE BETWEEN BASIC NEEDS SUCH AS FOOD OR SHELTER AND THEIR HEALTH CARE. IN AN EFFORT TO ALLEVIATE SUCH HARDSHIPS, LLS ESTABLISHED THE TRAVEL ASSISTANCE PROGRAM WHICH PROVIDES APPLICANTS, WHO ARE US CITIZENS OR PERMANENT RESIDENTS, HAVE AN ANNUAL INCOME AT OR BELOW 500% OF THE FEDERAL POVERTY LEVEL (FPL) AND HAVE A CONFIRMED BLOOD CANCER DIAGNOSIS, A ONE-TIME ANNUAL STIPEND TO HELP DEFER SOME OF THESE EXPENSES. LLS ROUTINELY CONDUCTS AN OPERATIONAL AUDIT VERIFYING APPLICANTS ARE IN COMPLIANCE WITH PROGRAM GUIDELINES AND PROGRAM CRITERIA. | ExplanationTxt |
Schedule J IRS990ScheduleJ
| Field | Value | IRS element (for citing) |
|---|---|---|
| Compensation Committee | Yes (X) | CompensationCommitteeInd |
| Independent Consultant | Yes (X) | IndependentConsultantInd |
| Form990 Of Other Organizations | Yes (X) | Form990OfOtherOrganizationsInd |
| Compensation Survey | Yes (X) | CompensationSurveyInd |
| Board Or Committee Approval | Yes (X) | BoardOrCommitteeApprovalInd |
| Severance Payment | Yes (true) | SeverancePaymentInd |
| Supplemental Nonqual Rtr Plan | false | SupplementalNonqualRtrPlanInd |
| Equity Based Comp Arrngm | false | EquityBasedCompArrngmInd |
| Comp Based On Revenue Of Flng Org | false | CompBasedOnRevenueOfFlngOrgInd |
| Comp Bsd On Rev Related Orgs | false | CompBsdOnRevRelatedOrgsInd |
| Comp Bsd Net Earns Flng Org | false | CompBsdNetEarnsFlngOrgInd |
| Comp Bsd Net Earns Rltd Orgs | false | CompBsdNetEarnsRltdOrgsInd |
| Any Non Fixed Payments | Yes (true) | AnyNonFixedPaymentsInd |
| Initial Contract Exception | false | InitialContractExceptionInd |
Rltd Org Officer Trst Key Empl RltdOrgOfficerTrstKeyEmplGrp (10 entries)
| TitleTitleTxt | Base Compensation Filing OrgBaseCompensationFilingOrgAmt | Bonus Filing OrganizationBonusFilingOrganizationAmount | Other Compensation Filing OrgOtherCompensationFilingOrgAmt | Deferred Compensation Flng OrgDeferredCompensationFlngOrgAmt | Nontaxable Benefits Filing OrgNontaxableBenefitsFilingOrgAmt | Total Compensation Filing OrgTotalCompensationFilingOrgAmt |
|---|---|---|---|---|---|---|
| LOUIS J DEGENNARO PHD | ||||||
| PRESIDENT & CEO | $599,504 | $330,000 | $21,012 | $14,537 | $26,721 | $991,774 |
| GWEN NICHOLS MD | ||||||
| EVP CHIEF MED OFFICE | $380,665 | $25,565 | $758 | $26,439 | $433,427 | |
| TROY DUNMIRE - START 1132020 | ||||||
| EVP CHIEF OPER OFFIC | $407,443 | $1,111 | $20,814 | $429,368 | ||
| VANESSA WHITE | ||||||
| SVP CHIEF ADV OFF | $354,266 | $1,201 | $4,703 | $21,514 | $381,684 | |
| LEE M GREENBERGER | ||||||
| SVP CHIEF SCIEN OFFI | $306,565 | $18,978 | $6,118 | $36,248 | $367,909 | |
| KATHY GRIESENBECK - END 7312020 | ||||||
| EVP CHIEF REL OFFICE | $214,806 | $132,900 | $6,365 | $11,492 | $365,563 | |
| COKER POWELL | ||||||
| EVP PROD CAMP DEV | $300,001 | $20,244 | $4,342 | $40,118 | $364,705 | |
| GORDON MILLER JR | ||||||
| EVP CHIEF FIN OFFICE | $319,573 | $1,655 | $6,469 | $29,843 | $357,540 | |
| MARGO LUCERO - END 7312020 | ||||||
| EVP CORP PARTNERSHIP | $199,983 | $136,383 | $19,808 | $356,174 | ||
| ROSEMARIE ALOFFREDO - END 3312019 | ||||||
| CHIEF FIN OFFICER | $177,503 | $177,503 | ||||
Supplemental Information Detail SupplementalInformationDetail (2 entries)
| Form And Line ReferenceFormAndLineReferenceDesc | ExplanationExplanationTxt |
|---|---|
| SCHEDULE J, PAGE 1, PART I, LINE 4 | KATHY GRIESENBECK - END 7/31/2020 127,308 0 0 MARGO LUCERO - END 7/31/2020 135,416 0 0 ROSEMARIE A.LOFFREDO - END 3/31/2019 177,503 0 0 |
| SCHEDULE J, PAGE 1, PART I, LINE 7 | BONUS WAS A RETENTION BONUS PAID BASED ON MILESTONE ACHIEVEMENT AS PER CONTRACT. |
Schedule M IRS990ScheduleM
Securities Publicly Traded SecuritiesPubliclyTradedGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Non Cash Checkbox | Yes (X) | NonCashCheckboxInd |
| Contribution | 217 | ContributionCnt |
| Noncash Contributions Rpt F990 | $1,575,597 | NoncashContributionsRptF990Amt |
| Method Of Determining Revenues | FAIR MARKET VALUE | MethodOfDeterminingRevenuesTxt |
Food Inventory FoodInventoryGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Non Cash Checkbox | Yes (X) | NonCashCheckboxInd |
| Contribution | 2 | ContributionCnt |
Other Non Cash Contri Table OtherNonCashContriTableGrp (2 entries)
| Non Cash CheckboxNonCashCheckboxInd | DescDesc | ContributionContributionCnt | Noncash Contributions Rpt F990NoncashContributionsRptF990Amt |
|---|---|---|---|
| Yes (X) | PRINTED ITEMS | 8 | |
| Yes (X) | VARIOUS OTHER | 35 | $208,680 |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Any Property That Must Be Held | false | AnyPropertyThatMustBeHeldInd |
| Review Process Unusual NC Gifts | Yes (true) | ReviewProcessUnusualNCGiftsInd |
| Third Parties Used | false | ThirdPartiesUsedInd |
Supplemental Information Detail SupplementalInformationDetail
| Field | Value | IRS element (for citing) |
|---|---|---|
| Form And Line Reference | SCHEDULE M, PAGE 2, PART II | FormAndLineReferenceDesc |
| Explanation | PART I, COLUMN (B) LLS IS REPORTING THE NUMBER OF CONTRIBUTIONS FOR EACH OF THE ITEMS IN PART I, NOT THE NUMBER OF INDIVIDUAL ITEMS. PART I, LINE 33 - EXPLANATION FOR NOT REPORTING REVENUE LLS ONLY RECORDS DONATED SECURITIES AS REVENUE. ALL OTHER ITEMS FOR WHICH COLUMN A IS CHECKED ARE NOT RECORDED AS REVENUE OR EXPENSE BECAUSE THEY WOULD NOT HAVE BEEN PURCHASED HAD THEY NOT BEEN DONATED, AND ARE IMMATERIAL IN AMOUNT RELATIVE TO THE STATEMENTS OF LLS. | ExplanationTxt |
Schedule O IRS990ScheduleO
Supplemental Information Detail SupplementalInformationDetail (12 entries)
| Form And Line ReferenceFormAndLineReferenceDesc | ExplanationExplanationTxt |
|---|---|
| FORM 990, PAGE 2, PART III, LINE 4A | A) RESEARCH PROGRAMS: AT LLS, WE ARE PUSHING BOUNDARIES TOWARD POWERFUL NEW THERAPIES. WE PROPEL GROUNDBREAKING CANCER TREATMENTS THROUGH ALL PHASES OF THE DRUG APPROVAL PROCESS AND ARE PROUD THAT OUR SUPPORT HAS BEEN KEY TO ADVANCING 75% OF THE ALMOST 100 BLOOD CANCER TREATMENT APPROVALS OVER THE LAST FIVE YEARS. AS WE CONTINUED TO SUPPORT THE SEARCH FOR LIFESAVING AND LESS TOXIC TREATMENTS IN 2021, WE INVESTED IN EXCITING RESEARCH FRONTIERS, INCLUDING PRECISION MEDICINE, IMMUNOTHERAPY, AND LINKS BETWEEN MUTATIONS AND BLOOD CANCER-ADVANCEMENTS THAT ARE CHANGING THE PARADIGM OF CANCER TREATMENT. IN THE PROCESS, WE PROPELLED SEVERAL NOVEL SCIENCE INITIATIVES TO NEW HEIGHTS-MANY OF WHICH HARDLY SEEMED POSSIBLE JUST A SHORT TIME AGO. WITH ADVISORY INPUT FROM RECOGNIZED BIOMEDICAL RESEARCH EXPERTS, LLS FUNDS EXEMPLARY PROJECTS ACROSS THE ENTIRE RESEARCH CONTINUUM RELEVANT TO IMPROVE OUTCOMES FOR BLOOD CANCER PATIENTS, FROM BASIC LABORATORY SCIENCE THROUGH CLINICAL TRIALS, AND FROM INVESTIGATOR-INITIATED RESEARCH TO PRIVATE-SECTOR DRUG DEVELOPMENT ALLIANCES. LLS IS DELIBERATE AND PURPOSEFUL IN FINDING AND SUPPORTING RESEARCH THAT IS MOST LIKELY TO HELP PATIENTS AS SOON AS POSSIBLE. TO DATE, LLS HAS INVESTED OVER 1.5 BILLION IN RESEARCH AIMED AT HELPING ALL BLOOD CANCER PATIENTS LIVE BETTER, LONGER LIVES. IN FISCAL YEAR 2021, LLS SUPPORTED RESEARCH IN THE U.S., CANADA AND 6 OTHER COUNTRIES WITH A TOTAL RESEARCH DISBURSEMENT OF APPROXIMATELY 33.9 MILLION. RESEARCH FUNDING WAS DISTRIBUTED ACROSS ALL BLOOD CANCERS. IMPACT RESEARCH GRANTS TO ADDRESS UNEQUAL REPRESENTATION OF UNDERSERVED POPULATIONS IN CLINICAL TRIALS, IN MAY WE INTRODUCED IMPACT (INFLUENTIAL MEDICINE PROVIDING ACCESS TO CLINICAL TRIALS) RESEARCH GRANTS. AN INITIAL FIVE-YEAR INVESTMENT OF 3.75 MILLION WAS ALLOCATED TO MAYO CLINIC, VANDERBILT UNIVERSITY MEDICAL CENTER, AND WEILL CORNELL MEDICINE IN NEW YORK CITY. THE IMPACT GRANTS WILL HELP THESE MAJOR CANCER CENTERS EXPAND CLINICAL TRIAL ACCESS TO LOCAL COMMUNITY-BASED HOSPITALS AND CLINICS WITH SUBSTANTIAL UNDERSERVED POPULATIONS. THE GOAL IS TO INCREASE TRIAL ENROLLMENT AMONG TRADITIONALLY UNDERSERVED POPULATIONS, INCLUDING RACIAL AND ETHNIC MINORITIES, RURAL RESIDENTS, AND INDIVIDUALS WITH LOW INCOME, TO AT LEAST 20%, THEREBY EXPANDING ACCESS TO STATE-OF-THE-ART THERAPIES TO A BROADER SWATH OF NEWLY DIAGNOSED BLOOD CANCER PATIENTS. THERAPY ACCELERATION PROGRAM (TAP) SINCE 2007, OUR INNOVATIVE VENTURE PHILANTHROPY INITIATIVE, THE LLS THERAPY ACCELERATION PROGRAM (TAP), HAS PARTNERED WITH BIOTECHNOLOGY COMPANIES AND ACADEMIC RESEARCHERS TO EXTEND THE THERAPEUTIC LANDSCAPE IN LEUKEMIA, LYMPHOMA, AND MULTIPLE MYELOMA. IN 2021, WE MADE SIX NEW INVESTMENTS IN COMPANIES DEVELOPING NEW IMMUNOTHERAPIES INCLUDING "OFF THE SHELF" CAR T-CELL THERAPY, "IN VIVO" THERAPY THAT GENERATES CANCER-FIGHTING CAR CELLS INSIDE THE BODY, TWO FIRST-IN-CLASS ANTIBODIES TARGETING NOVEL CHECKPOINTS, TO RELEASE THE BRAKES AND ACTIVATE IMMUNE CELLS SO THEY CAN FIGHT CANCER, AND CAR- MACROPHAGE (CAR-M) THERAPY TO TREAT CANCERS WHERE CHECKPOINT INHIBITORS TEND TO BE LESS EFFECTIVE. NATIONAL PATIENT REGISTRY COVID INFORMATION THE ONGOING COVID-19 PANDEMIC ENGENDERED A HOST OF FEARS AND QUESTIONS FOR THE BLOOD CANCER COMMUNITY. WHEN PATIENT CONCERNS AROSE ABOUT WHETHER THE NEW VACCINES WOULD PROTECT THEM, LLS STEPPED IN TO FIND ANSWERS. IN FEBRUARY 2021, LLS ACTIVATED THE LLS NATIONAL PATIENT REGISTRY, A PROJECT SUPPORTED BY ETHEL AND BERNARD GARIL IN MEMORY OF THEIR SON, MICHAEL, WHO SUCCUMBED TO ACUTE LYMPHOBLASTIC LEUKEMIA. MORE THAN 10,000 BLOOD CANCER PATIENTS ANSWERED THE CALL TO JOIN THE REGISTRY AS "CITIZEN SCIENTISTS." THIS ALLOWED US TO GENERATE THE LARGEST DATA SET REPORTED TO DATE ON VACCINE SAFETY AND EFFICACY(INCLUDING BOOSTERS) ACROSS ALL MAJOR BLOOD CANCER AND TREATMENT TYPES. THIS INFORMATION HAS HELPED PATIENTS, HEALTHCARE PROVIDERS, AND PUBLIC HEALTH OFFICIALS MAKE MORE INFORMED CHOICES ABOUT COVID-19 PREVENTION. CLINICAL TRIALS BEAT AML MASTER TRIAL BEGINNING NOVEMBER 2016, LLS LAUNCHED THE BEAT AML MASTER TRIAL, A COLLABORATIVE CLINICAL TRIAL TESTING SEVERAL NOVEL TARGETED THERAPIES FOR PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) DESIGNED TO FACILITATE FDA APPROVAL OF NEW DRUGS AND CHANGE THE TREATMENT PARADIGM FOR PATIENTS DIAGNOSED WITH AML BY DEVELOPING MORE INDIVIDUALIZED, EFFECTIVE TREATMENT APPROACHES. THE MASTER TRIAL INVOLVES COLLABORATIONS WITH MULTIPLE MEDICAL INSTITUTIONS, DRUG COMPANIES, A GENOMIC PROVIDER, A CLINICAL RESEARCH ORGANIZATION, AND THE FDA, ALL OF WHOM HAVE COMMITTED TO WORKING COLLABORATIVELY. IN FISCAL YEAR 2021, UP TO 35 PATIENTS PARTICIPATED IN CLINICAL TRIALS UNDER THE BEAT AML MASTER TRIAL. |
| FORM 990, PAGE 2, PART III, LINE 4B | B) PATIENT & COMMUNITY SERVICES: AN ESTIMATED 1.3 MILLION PEOPLE ACROSS THE UNITED STATES (US) ARE CURRENTLY LIVING WITH OR ARE IN REMISSION FROM LEUKEMIA, LYMPHOMA AND MYELOMA. THE LEUKEMIA & LYMPHOMA SOCIETY (LLS) OFFERS AN ARRAY OF FREE, COMPREHENSIVE RESOURCES TO BLOOD CANCER PATIENTS, CAREGIVERS, FAMILIES AND FRIENDS OF PATIENTS, ADVOCATES, HEALTHCARE PROFESSIONALS AND THE PUBLIC. LLS IS COMMITTED TO PROVIDING THE MOST ACCURATE AND UP-TO-DATE BLOOD CANCER INFORMATION. PROFESSIONAL VOLUNTEER CLINICAL ADVISORS WORK WITH LLS STAFF TO REVIEW ALL OF THE INFORMATION LLS PROVIDES THROUGH HEALTHCARE PROFESSIONAL AND PATIENT EDUCATION PROGRAMS, PUBLICATIONS AND THE LLS WEBSITE. SUPPORT SERVICES ARE PROVIDED BY PROFESSIONALS OR RIGOROUSLY TRAINED PEER VOLUNTEERS. ALL RESOURCES ARE PROVIDED THROUGH A VARIETY OF MEDIA - PRINT, ONLINE, BY PHONE, AND FACE-TO-FACE IN COMMUNITIES. A NUMBER OF RESOURCES ARE AVAILABLE IN SPANISH FOR PATIENTS, CAREGIVERS AND HEALTHCARE PROFESSIONALS. FINANCIAL ASSISTANCE OUR FINANCIAL ASSISTANCE PROGRAMS AIM TO LESSEN THE ECONOMIC TOLL ON PATIENTS AND FAMILIES TO HELP PATIENTS AFFORD LIFE-SAVING TREATMENTS. TO COUNTER CONTINUALLY RISING DRUG PRICES AND THE ONGOING FINANCIAL IMPACT OF COVID-19, WE PROVIDED MORE THAN 45,000 PATIENTS WITH OVER 241M IN TOTAL GRANTS, A 70% INCREASE OVER LAST YEAR. THE LION'S SHARE-OVER 234 MILLION- SUPPORTED PATIENTS' INSURANCE PREMIUMS AND TREATMENT-RELATED CO-PAY AND CO-INSURANCE OUT OF POCKET COSTS THROUGH OUR CO-PAY ASSISTANCE PROGRAM. IN KEEPING WITH OUR COMMITMENT TO DIVERSITY, EQUITY, AND INCLUSION, LLS RECOGNIZES THAT NEED EXISTS THROUGHOUT ALL GEOGRAPHIC REGIONS AND WITHIN ALL PATIENT POPULATIONS, INCLUDING THOSE TRADITIONALLY UNDERREPRESENTED. IN 2021, FINANCIAL ASSISTANCE WAS PROVIDED TO PATIENTS WHO RESIDED IN 55% OF ALL U.S. COUNTIES AND 51% OF THE COUNTIES ACROSS THE U.S. WITH THE HIGHEST POVERTY RATES. CO-PAY ASSISTANCE PROGRAM THE CO-PAY ASSISTANCE PROGRAM SUPPORTS QUALIFYING BLOOD CANCER PATIENTS MEET THEIR HEALTH INSURANCE OR MEDICARE PLAN PART B OR D PREMIUMS OR CO- PAYMENT OBLIGATIONS RELATED TO TREATING THEIR BLOOD CANCER DIAGNOSIS. PATIENTS WITH PRESCRIPTION DRUG COVERAGE, MEDICARE BENEFICIARIES UNDER MEDICARE PART B AND/OR MEDICARE PART D, MEDICARE SUPPLEMENTARY HEALTH INSURANCE OR MEDICARE ADVANTAGE SHOULD CHECK WITH LLS TO SEE IF THEY MEET ELIGIBILITY REQUIREMENTS TO RECEIVE FINANCIAL SUPPORT. CO-PAY ASSISTANCE IS SUBJECT TO FUNDING AVAILABILITY BY SPECIFIC BLOOD CANCER DIAGNOSIS. IN 2021, CO-PAY ASSISTANCE WAS PROVIDED TO OVER 22,000 PATIENTS. SUSAN LANG PRE CAR T-CELL THERAPY TRAVEL ASSISTANCE PROGRAM LLS PROVIDED OVER 200 GRANTS, EACH 2,500, FOR TREATMENT-RELATED TRANSPORTATION AND LODGING COSTS FOR PATIENTS WHO ARE BEING EVALUATED TO RECEIVE CAR T-CELL THERAPY AS EITHER STANDARD TREATMENT OR A CLINICAL TRIAL. SUSAN LANG PAY-IT-FORWARD PATIENT TRAVEL ASSISTANCE PROGRAM LLS AWARDED A 500 GRANT TO OVER 4,750 PATIENTS FOR TREATMENT-RELATED TRANSPORTATION AND LODGING COSTS. URGENT NEED PROGRAM IN PARTNERSHIP WITH MOPPIE'S LOVE AND CHARLIE'S FUND, LLS PROVIDED A 500 GRANT TO NEARLY 9,000 PATIENTS AND FAMILIES IN ACUTE FINANCIAL NEED FOR NON-MEDICAL LIVING EXPENSES-INCLUDING RENT, UTILITIES AND FOOD. PATIENT AID PROGRAM LLS PROVIDED A ONE-TIME STIPEND OF 100 TO OVER 3,700 PATIENTS TO HELP OFFSET NON-MEDICAL EXPENSES. SCHOLARSHIP FOR BLOOD CANCER SURVIVORS NEW IN 2021 WAS THE INTRODUCTION OF LLS'S SCHOLARSHIP FOR BLOOD CANCER SURVIVORS PROVIDING UP TO 7,500 IN TUITION SUPPORT FOR PATIENTS DIAGNOSED BEFORE AGE 25, ARE U.S. CITIZENS OR PERMANENT RESIDENTS PURSUING VIRTUAL OR IN-PERSON, VOCATIONAL, 2 YEAR OR 4 YEAR POST-SECONDARY EDUCATION. |
| FORM 990, PAGE 2, PART III, LINE 4C | C) PUBLIC HEALTH EDUCATION: LLS BELIEVES KNOWLEDGE IS POWER. AS ALWAYS, LLS HAS OFFERED THEIR INFORMATIONAL PROGRAMS IN VIRTUAL FORMATS, CONTINUING TO PROVIDE VITALLY NEEDED EDUCATION AND EMOTIONAL SUPPORT FOR THOSE IMPACTED BY BLOOD CANCER. ONGOING PANDEMIC CONCERNS TRAINED ONCOLOGY INFORMATION SPECIALISTS IN OUR INFORMATION RESOURCE CENTER (IRC) WERE AVAILABLE TO ANSWER PANDEMIC-RELATED AND OTHER QUESTIONS. OVER 26,000 INTERACTIONS BETWEEN THE IRC AND PATIENTS AND CAREGIVERS TOOK PLACE, WITH AVERAGE CALL LENGTHS UP 30% OVER 2020. FACILITATING CLINICAL TRIAL ACCESS THE LLS CLINICAL TRIAL SUPPORT CENTER (CTSC) GREW THROUGHOUT THE YEAR AS WE INCREASED OUR BI-LINGUAL AND PEDIATRIC EXPERTISE AMONG THE CTSC NURSE NAVIGATORS, AND CONTINUED TO EXPAND THE POSSIBILITY OF POSITIVE OUTCOMES FOR PATIENTS BY MATCHING THEM TO SUITABLE CLINICAL TRIALS. OUR NURSE NAVIGATORS ASSISTED 1,019 PATIENTS (UP 31% FROM 2020). OF THE 759 NEW PATIENTS ASSISTED (UP 31% FROM LAST YEAR), 21% ENTERED A TRIAL. WE WERE HONORED THAT A CTSC TEAM-AUTHORED ARTICLE, OVERCOMING BARRIERS TO CLINICAL TRIAL PARTICIPATION: OUTCOMES OF A NATIONAL CLINICAL TRIAL MATCHING AND NAVIGATION SERVICE FOR PATIENTS WITH A BLOOD CANCER, WAS PUBLISHED IN THE "JOURNAL OF CLINICAL ONCOLOGY, ONCOLOGY PRACTICE" IN MAY. OUTREACH TO UNDERSERVED GROUPS WE AUGMENTED EFFORTS TO EXPAND ACCESS TO LLS SERVICES AND RESOURCES BY BOLSTERING RELATIONS WITH COMMUNITY GROUPS AND LEADERS, NOTABLY IN THE AFRICAN AMERICAN AND LATINO COMMUNITIES, AND INCREASED OUR NUMBER OF BILINGUAL VOLUNTEERS. WE ALSO INCREASED ACCESSIBILITY OF OUR EDUCATION PROGRAMS TO RURAL PATIENTS AND FAMILIES VIA OUR VIRTUAL OFFERINGS. MOREOVER, WE EXPANDED PARTNERSHIPS WITH AFFINITY GROUPS INCLUDING: THE COALITION OF 100 BLACK WOMEN, THE MEXICAN CONSULATE'S VENTANILLA DE SALUD PROGRAM,AND PROMOTORES (VISION Y COMPROMISO). THE LLS MYELOMA LINK PROGRAM, LAUNCHED IN 2017, CONTINUED TO GAIN TRACTION. WE IMPROVED UNDERSTANDING OF TREATMENT OPTIONS BY PROVIDING IMPORTANT INFORMATION TO AFRICAN AMERICANS, WHO ARE TWICE AS LIKELY TO BE DIAGNOSED WITH MULTIPLE MYELOMA AS CAUCASIAN AMERICANS. IN 2021, LLS REACHED APPROXIMATELY 10,448 PEOPLE THROUGH MORE THAN 72 MYELOMA LINK EDUCATION AND OUTREACH ACTIVITIES IN 13 CITIES. EDUCATION AND PATIENT CONNECTIONS OUR VIRTUAL EDUCATION PROGRAMS PROVIDED BOTH PATIENTS AND FAMILIES, AS WELL AS HEALTH CARE PROFESSIONALS, ACCESS TO CONTENT INCLUDING BLOOD CANCER CONFERENCES, LOCAL EDUCATION PROGRAMS, NATIONAL WEBINARS, VIDEOS, LECTURES, AND PODCASTS. LLS'S HIGHLY VIEWED WEBSITE CONTINUES TO PROVIDE THE MOST UP TO DATE BLOOD CANCER INFORMATION INCLUDING ACCESS TO BLOGS, BOOKLETS, WORKBOOKS, FACT SHEETS AND MORE. IN ADDITION, NEARLY 1,000 CANCER PATIENTS WERE PROVIDED WITH PERSONALIZED NUTRITION CONSULTATIONS BY LLS'S REGISTERED DIETITIAN. OUR PATIENT & COMMUNITY OUTREACH TEAM CONTINUED TO BRING PATIENTS TOGETHER VIA ONLINE LOCAL SUPPORT GROUPS AND CHATS. THE PATTI ROBINSON KAUFMANN FIRST CONNECTION PROGRAM MATCHED NEARLY 1,800 PATIENTS (UP 5% FROM 2020) WITH TRAINED VOLUNTEERS FACING THE SAME DISEASE, HELPING TO AVERT PANDEMIC-RELATED ISOLATION. IN ADDITION, MEMBERSHIP IN LLS COMMUNITY-OUR ONLINE SOCIAL NETWORK-INCREASED 23% OVER 2020. |
| FORM 990, PAGE 2, PART III, LINE 4D | D) PROFESSIONAL EDUCATION: LLS SERVES THE EDUCATIONAL NEEDS OF THE MEDICAL AND RESEARCH COMMUNITY THROUGH A NUMBER OF PROFESSIONAL EDUCATION SYMPOSIA OFFERED THROUGHOUT THE YEAR. THE EDUCATIONAL PROGRAM OFFERS VARYING FORMATS TO FACILITATE THE EXCHANGE OF INFORMATION AND IDEAS ON THE NEWEST DEVELOPMENTS IN CANCER RESEARCH AND TREATMENT. UPCOMING AND ARCHIVED CE/CME PROGRAMS ARE AVAILABLE AT WWW.LLS.ORG/CE. IN FY 2021: -LLS PROVIDED 14 CME/CE-GRANTING VIRTUAL EDUCATIONAL PROGRAMS, WITH 2,345 HEALTHCARE PROFESSIONALS IN ATTENDANCE. --THERE WERE 44,790 PAGE VIEWS FOR ARCHIVED WEB PROGRAMS, 25,541 VIRTUAL LECTURE VIEWS AND 14,107 PODCAST DOWNLOADS. |
| FORM 990, PART V, LINE 4B | CANADA |
| FORM 990, PAGE 6, PART VI, LINE 11B | THE FORM 990 WAS PREPARED BY THE LLS FINANCE DEPARTMENT AND WAS REVIEWED BY THE CFO, VICE PRESIDENT, CONTROLLER, AND KPMG FOR COMMENT AND SUGGESTED REVISIONS. THE FORM 990 WAS THEN PROVIDED TO THE AUDIT COMMITTEE, WHICH IS A COMMITTEE OF THE BOARD OF DIRECTORS. THE AUDIT COMMITTEE REVIEWED THE 990 AND PROVIDED INPUT PRIOR TO FILING. THE FINAL DRAFT FORM 990, AS WILL BE FILED WITH THE IRS, WAS PROVIDED TO THE ENTIRE BOARD OF DIRECTORS PRIOR TO FILING WITH THE IRS. |
| FORM 990, PAGE 6, PART VI, LINE 12C | ALL EMPLOYEES, VOLUNTEERS, CONSULTANTS, TEMPORARY EMPLOYEES, LOCAL BOARD MEMBERS, AND MEMBERS OF THE NATIONAL BOARD OF DIRECTORS ARE REQUIRED TO REVIEW THE CONFLICT OF INTEREST POLICY ON AN ANNUAL BASIS AND SUBMIT A SIGNED FORM ACKNOWLEDGING THAT THEY HAVE REVIEWED THE POLICY AND DISCLOSED ANY CONFLICTS OF INTEREST. ALL CONFLICT OF INTEREST DISCLOSURE FORMS ARE REVIEWED BY THE LEGAL DEPARTMENT AND, IF DEEMED NECESSARY, ESCALATED TO THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS FOR FURTHER REVIEW, EVALUATION, AND/OR MANAGEMENT OF ANY ACTUAL OR APPARENT CONFLICTS OF INTEREST. |
| FORM 990, PAGE 6, PART VI, LINE 15A | THE EXECUTIVE COMMITTEE COMPRISED OF INDEPENDENT MEMBERS OF THE BOARD OF DIRECTORS REVIEWS, MONITORS, AND APPROVES THE CHIEF EXECUTIVE OFFICER'S PERFORMANCE AND COMPENSATION. THEIR DECISION IS INCLUDED IN THE APPROPRIATE MINUTES OF THE MEETING IN WHICH APPROVAL WAS GIVEN. IN 2020, THE EXECUTIVE COMMITTEE, THROUGH AN INDEPENDENT THIRD PARTY, OBTAINED A MARKET STUDY COMPRISED OF SIMILAR NOT-FOR-PROFIT ORGANIZATIONS TO REVIEW THE COMPENSATION MARKET LEVELS AND SET THE CHIEF EXECUTIVE'S SALARY COMMENSURATELY. THE COMMITTEE MET, APPROVED AND DOCUMENTED THE PROCESS IN THE COMMITTEE MINUTES. |
| FORM 990, PAGE 6, PART VI, LINE 15B | IN 2020, THE EXECUTIVE COMMITTEE, THROUGH AN INDEPENDENT THIRD PARTY, OBTAINED A MARKET STUDY COMPRISED OF SIMILAR NOT-FOR-PROFIT ORGANIZATIONS TO REVIEW THE COMPENSATION MARKET LEVELS OF OTHER OFFICERS AND KEY EMPLOYEES AND TO APPROVE THE PRESIDENT AND CEO'S RECOMMENDATIONS ON THEIR COMPENSATION LEVELS. |
| FORM 990, PAGE 6, PART VI, LINE 17 | ILLINOIS, INDIANA, KANSAS, KENTUCKY, LOUISIANA, MASSACHUSETTS, MARYLAND, MAINE, MICHIGAN, MINNESOTA, MISSOURI, MISSISSIPPI, NEW HAMPSHIRE, NEW JERSEY, NEW MEXICO, NEBRASKA, NEW YORK, OHIO, OKLAHOMA, OREGON, PENNSYLVANIA, PUERTO RICO, RHODE ISLAND, SOUTH CAROLINA, TENNESSEE, UTAH, VIRGINIA, WASHINGTON, WISCONSIN, WEST VIRGINIA |
| FORM 990, PAGE 6, PART VI, LINE 19 | THE LEUKEMIA & LYMPHOMA SOCIETY, INC. MAKES ITS ANNUAL FINANCIAL STATEMENTS AVAILABLE TO THE PUBLIC ON ITS WEBSITE AT WWW.LLS.ORG. ITS GOVERNING DOCUMENTS ARE MADE AVAILABLE UPON REQUEST FOR PUBLIC INSPECTION. ANY IDENTIFIED CONFLICTS OF INTEREST ARE DISCLOSED IN THE 990. |
| FORM 990, PART XI, LINE 9 | MISC ROUNDING -2,054 |
Schedule R IRS990ScheduleR
Id Disregarded Entities IdDisregardedEntitiesGrp (13 entries)
| Address Line1USAddress/AddressLine1Txt | CityUSAddress/CityNm | State AbbreviationUSAddress/StateAbbreviationCd | ZIPUSAddress/ZIPCd | Primary ActivitiesPrimaryActivitiesTxt | Legal Domicile StateLegalDomicileStateCd | Total IncomeTotalIncomeAmt | End Of Year AssetsEndOfYearAssetsAmt | Business Name Line1DirectControllingEntityName/BusinessNameLine1Txt |
|---|---|---|---|---|---|---|---|---|
| BEAT AML LLC | ||||||||
| 3 INTERNATIONAL DRIVE | RYE BROOK | NY | 10573 | RESEARCH | NY | $12,281,252 | $4,921,911 | LLS |
| LLS PEDAL INITIATIVE LLC | ||||||||
| 3 INTERNATIONAL DRIVE | RYE BROOK | NY | 10573 | RESEARCH | NY | -$1,187,768 | LLS | |
| LLS TAP FORTY SEVEN LLC | ||||||||
| 3 INTERNATIONAL DRIVE | RYE BROOK | NY | 10573 | RESEARCH | NY | LLS | ||
| LLS TAP MIRAGEN LLC | ||||||||
| 3 INTERNATIONAL DRIVE | RYE BROOK | NY | 10573 | RESEARCH | NY | LLS | ||
| LLS TAP X4 LLC | ||||||||
| 3 INTERNATIONAL DRIVE | RYE BROOK | NY | 10573 | RESEARCH | NY | $1,980,000 | LLS | |
| LLS TAP LLC | ||||||||
| 3 INTERNATIONAL DRIVE | RYE BROOK | NY | 10573 | RESEARCH | NY | $2,869,351 | $4,588,434 | LLS |
| LLS TAP CONSTELLATION LLC | ||||||||
| 3 INTERNATIONAL DRIVE | RYE BROOK | NY | 10573 | RESEARCH | NY | LLS | ||
| LLS TAP AFFIRMED LLC | ||||||||
| 3 INTERNATIONAL DRIVE | RYE BROOK | NY | 10573 | RESEARCH | NY | LLS | ||
| LLS TAP SUTRO LLC | ||||||||
| 3 INTERNATIONAL DRIVE | RYE BROOK | NY | 10573 | RESEARCH | NY | LLS | ||
| LLS TAP JOHNS HOPKINS LLC | ||||||||
| 3 INTERNATIONAL DRIVE | RYE BROOK | NY | 10573 | RESEARCH | NY | LLS | ||
| LLS TAP SELVITA LLC | ||||||||
| 3 INTERNATIONAL DRIVE | RYE BROOK | NY | 10573 | RESEARCH | NY | LLS | ||
| LLS TAP VERASTEM LLC | ||||||||
| 3 INTERNATIONAL DRIVE | RYE BROOK | NY | 10573 | RESEARCH | NY | LLS | ||
| LLS TAP KDAC LLC | ||||||||
| 3 INTERNATIONAL DRIVE | RYE BROOK | NY | 10573 | RESEARCH | NY | LLS | ||
Id Related Tax Exempt Org IdRelatedTaxExemptOrgGrp (3 entries)
| Address Line1USAddress/AddressLine1Txt | CityUSAddress/CityNm | State AbbreviationUSAddress/StateAbbreviationCd | ZIPUSAddress/ZIPCd | EINEIN | Primary ActivitiesPrimaryActivitiesTxt | Legal Domicile StateLegalDomicileStateCd | Exempt Code SectionExemptCodeSectionTxt | Public Charity StatusPublicCharityStatusTxt | Business Name Line1DirectControllingEntityName/BusinessNameLine1Txt | Controlled OrganizationControlledOrganizationInd | Address Line1ForeignAddress/AddressLine1Txt | CityForeignAddress/CityNm | CountryForeignAddress/CountryCd | Foreign PostalForeignAddress/ForeignPostalCd | Legal Domicile Foreign CountryLegalDomicileForeignCountryCd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| THE LLS RESEARCH PROGRAMS INC | |||||||||||||||
| 3 INTERNATIONAL DRIVE | RYE BROOK | NY | 10573 | 133470494 | PART VII | DE | 501C3 | 12A | LLS INC | Yes (true) | |||||
| THE LLS RESEARCH FOUNDATION | |||||||||||||||
| 3 INTERNATIONAL DRIVE | RYE BROOK | NY | 10573 | 133709252 | PART VII | DE | 501C3 | 12A | LLS INC | Yes (true) | |||||
| THE LLS OF CANADA | |||||||||||||||
| PART VII | NA | false | 804 2 LANSING SQUARE | TORONTO | CA | M2J4P8 | CA | ||||||||
| Field | Value | IRS element (for citing) |
|---|---|---|
| Receipt Of Int Annts Rnts Rylts | false | ReceiptOfIntAnntsRntsRyltsInd |
| Gift Grnt Or Cap Contri To Oth Org | false | GiftGrntOrCapContriToOthOrgInd |
| Gift Grnt Cap Contri From Oth Org | false | GiftGrntCapContriFromOthOrgInd |
| Loans Or Guarantees To Other Org | false | LoansOrGuaranteesToOtherOrgInd |
| Loans Or Guarantees From Oth Org | false | LoansOrGuaranteesFromOthOrgInd |
| Div Related Organization | false | DivRelatedOrganizationInd |
| Asset Sale To Other Org | false | AssetSaleToOtherOrgInd |
| Asset Purchase From Other Org | false | AssetPurchaseFromOtherOrgInd |
| Asset Exchange | false | AssetExchangeInd |
| Rental Of Facilities To Oth Org | false | RentalOfFacilitiesToOthOrgInd |
| Rental Of Fclts From Oth Org | false | RentalOfFcltsFromOthOrgInd |
| Perform Of Services For Oth Org | false | PerformOfServicesForOthOrgInd |
| Perform Of Services By Other Org | false | PerformOfServicesByOtherOrgInd |
| Sharing Of Facilities | false | SharingOfFacilitiesInd |
| Paid Employees Sharing | false | PaidEmployeesSharingInd |
| Reimbursement Paid To Other Org | false | ReimbursementPaidToOtherOrgInd |
| Reimbursement Paid By Other Org | false | ReimbursementPaidByOtherOrgInd |
| Transfer To Other Org | false | TransferToOtherOrgInd |
| Transfer From Other Org | false | TransferFromOtherOrgInd |
Supplemental Information Detail SupplementalInformationDetail
| Field | Value | IRS element (for citing) |
|---|---|---|
| Form And Line Reference | SCHEDULE R | FormAndLineReferenceDesc |
| Explanation | THE LEUKEMIA & LYMPHOMA SOCIETY OF CANADA CARRIES OUT THE SAME PRIMARY ACTIVITIES AS THE LEUKEMIA & LYMPHOMA SOCIETY, INC., BUT IN CANADA. THE LEUKEMIA SOCIETY RESEARCH PROGRAMS, INC. AND THE LEUKEMIA RESEARCH FOUNDATION, INC. SUPPORT THE ACTIVITIES OF THE LEUKEMIA & LYMPHOMA SOCIETY, INC. | ExplanationTxt |
Comments